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INTRODUCTION 
ANATOMY OF ANTERIOR CHAMBER ANGLE 
 
 Anterior chamber is the space filled by aqueous humor in eye, bound in 
front by the posterior surface of cornea and behind by the anterior surface of 
iris and part of anterior surface of lens which is exposed at pupil. Its 
peripheral recess is known as angle of anterior chamber, which is bounded 
posteriorly by the root of iris and ciliary body and anteriorly, by corneo-
sclera. In the innermost  layer of sclera, there is a circular venous sinus called 
canal of Schlemm, which is significant in the drainage of aqueous humor. 
Between the Schlemm’s canal and the recess of anterior chamber lies the 
trabecular eshwork. It is triangular in shape, the apex arising from the 
termination of descemets membrane and the adjacent corneal stroma and its 
base merging into the tissue of ciliary body with iris root.  
Gonioscopic anatomy :  
o When the anterior chamber is visualized with gonioscopic lens, 
following structures are seen from posterior to anterior:  
Ø Root of iris  
Ø Ciliary body  
Ø Scleral spur 
Ø Trabecular meshwork  
 
 
Ø Schwalbe’s line  
Ciliary body  
Ciliary body is well seen in gonioscopy when the angle is wide open. 
This part of angle is covered by anterior stroma of iris known as uveal 
meshwork.  
Scleral spur  
 It is formed by protrusion of sclera internally which forms the posterior 
concavity of scleral spur. The spur is also the insertion of longitudinal muscle 
fibers of ciliary body whose action alters the facility of aqueous humor 
outflow.  
Trabecular meshwork  
 Between Schwalbe’s line and scleral spur stretches the perforated 
layers of connective tissue sheet of trabecular meshwork through which 
aqueous flows into Schlemm’s canal.  
Schwalbe’s line (Anterior border ring)  
 It is the termination of descemet’s membrane of cornea. It is formed by 
bundle of collagenous connective tissue and elastic fibers in the terminal 
region of the descemets membrane. 
 
 
 
 
Schlemm’s canal and collector channels  
 Schlemm’s canal is situated at corneoscleral junction at the bottom of 
scleral furrow, with its apex towards the descemet’s membrane. It is drained 
by aqueous veins and collector channels, which drain the aqueous into 
episcleralsubconjunctival venous plexus. The collector channels are about 20- 
25 in number. 
INTRODUCTION TO GLAUCOMA 
 Glaucoma is the third leading cause of blindness in India. Around 12 
million people are affected in our country, thus accounting for 12.8% of the 
country’s blindness prevalence. Population based studies have report a 
prevalence between 2 to 13 %. On basis of the current data as reported by the 
Andhra Pradesh Eye Disease Study(APES) ,Vellore Eye Survey(VES), 
Chennai Glaucoma Study (CGS),Aravind Comprehensive Eye 
Survey(ACES) , and also West Bengal Glaucoma Study(WBGS), it is 
estimated that there are around 11.2 million persons aged above 40 years with 
glaucoma in India. Patients with any type of primary angle-closure disease 
could number around 27.6 million of the entire population. 
 
.  
 
 
 
 
Definition of glaucoma:  
 Glaucoma is a progressive optic neuropathy characterized by optic 
nerve head damage and visual field changes. Deterioration to the visual 
system in glaucoma disease is due to the death  and apoptosis of the retinal 
ganglion cells,  and their axons which comprise the optic nerve and carryout 
the visual impulses from the ocular system to our brain. 
PRIMARY ANGLE CLOSURE GLAUCOMA 
 Primary angle closure glaucoma (PACG) is second to POAG as the 
most prevalent type of glaucoma worldwide but is more commonly associated 
with blindness than POAG. High risk groups of  PACG are people with small 
and short  eyeballs, hyperopic, females, Old age, and also in ethnic groups 
like Chinese and also Eskimos.  
 Primary angle closure glaucoma occurs when the iris bows forward and 
obstructs the anterior chamber angle. When the anterior chamber angle is 
obstructed by iris, fluid can no longer drain out of the eye. Since fluid 
production continues despite its impaired drainage, fluid as well as 
intraocular pressure buildup within the eye. Increased IOP is believed to be 
the cause of optic nerve damage in PACG.  
. 
 
 
 
DEFINITION: 
 Angle-closure glaucoma is defined as apposition of the peripheral iris 
against the trabecular meshwork(TM), which results in obstruction of the 
aqueous outflow.  
Conditions that have been included in this group are 
1. Pupillary-block glaucoma 
2. Plateau iris 
3. Combined mechanism glaucoma.  
Other forms of angle-closure glaucoma are called secondary angle-closure 
glaucoma because of the  associated ocular (or) systemic associations as well 
as due to more apparent mechanisms of angle closure that pull the angle 
closed or space occupying lesions that push and close the angles.  
As continued research has expanded our knowledge concerning the 
associated abnormalities and mechanisms of primary angle-closure 
glaucomas, the distinction between the primary and secondary types of  ACG 
has become increasingly artificial, and the concept should probably be 
abandoned. mechanism of plateau iris, it is now considered with the 
glaucomas associated with disorders of the iris and ciliary body  
 
 
 
 
 
PUPILLARY-BLOCK GLAUCOMA 
 Pupillary-block glaucoma, is a type of angle-closure glaucoma, is the 
most common form. The cause initiating event is thought to result from 
increased resistance to flow of aqueous humor between the pupillary part of 
the iris and the anterior lens capsular surface, which is associated with mid-
dilatation of the pupil. 
 The functional block produces increased fluid intraocular pressure 
(IOP) in the ocular posterior chamber, which in turn causing forward shift of 
the iris structures. Anterior movement of the peripheral iris can result in 
closure of the anterior chamber angle. 
Four forms of pupillary-block glaucoma may be distinguished on the basis of 
symptoms and clinical findings:  
1. Acute angle-closure glaucoma,  
2. Subacute angle-closure glaucoma 
3. Chronic angle-closure glaucoma 
4. Combined-mechanism glaucoma. 
Acute Angle-Closure Glaucoma 
 In acute angle-closure glaucoma, the manifestations are sudden and 
severe, with marked pain, blurred vision, and a red eye. and may or may not 
be associated with nausea and vomiting. 
 
 
 
Subacute Angle-Closure Glaucoma 
 Subacute angle-closure glaucoma is believed to have the same 
pupillary-block mechanism as the acute angle closure, but symptoms can be 
mild or absent.  
   The condition has also been called intermittent, prodromal, or 
subclinical.Patients with subacute angle-closure glaucoma may have multiple 
subacute or subclinical attacks before finally having an acute attack or 
developing peripheral anterior synechiae associated with chronic pressure 
elevation. 
Chronic Angle-Closure Glaucoma 
 In chronic angle-closure glaucoma, the portions of the anterior 
chamber angle are usually permanently closed by peripheral anterior 
synechiae, and the intraocular pressure (IOP) is  elevated  for a longer 
duration.The synechial closure may result from a prolonged acute attack or 
repeated subacute attacks of angle-closure glaucoma.  
       A variation of this condition is referred to as shortening of the angle or 
creeping angle-closure glaucoma. It is important to look carefully for 
evidence of pseudoexfoliation syndrome, because pseudoexfoliation can 
always predispose to pupillary block in certain patient groups. 
 
 
 
 
Combined Mechanism Glaucoma 
    In some eyes, the glaucoma appears to have combined mechanism of 
open-angle and angle-closure mechanisms. The diagnosis is usually made 
after an acute angle-closure glaucoma attack in which the IOP remains 
elevated after a peripheral iridotomy, despite an open, normal-appearing 
angle.  
 In one study, this was seen in 6 (2.2%) of 267 eyes that underwent 
peripheral iridectomy for presumed angle-closure glaucoma. 
Twenty-first century consensus classification 
 The new classification of primary angle-closure (PAC) disease is based 
on 3 simple parameters: IOP measurement, gonioscopy, and disc and visual 
field evaluation. 
  In other words, the presenting patient’s clinical examination findings 
alone decides the  correct staging of  disease presentation,regardless of  
presence or the absence of symptom history, alleged duration of illness, 
intermittency of problems, etc. 
1. Primary angle closure Suspect (PAC suspect): 
         More than 270° of irido-trabecular contact seen with absent  peripheral 
anterior synechiae (“PAS”) plus normal range of IOP, disc changes, and 
visual field. In other words, the suspect eye has normal IOPs, optic nerves 
and visual fields, i.e., no signs of clinical glaucoma, but those of which angle 
 
 
before indentation gonioscopy is classified as a Shaffer grade II or lesser, 
without peripheral anterior synechiae (PAS) on compression. The angle is at 
risk for PACG 
2. Primary angle CLOSURE (PAC): 
        Greater than 270° of irido-trabecular contact with either elevated IOP 
and/or PAS plus normal disc and visual field examinations.  
       In other words, angle closure can be demonstrated as irido-trabecular 
contact in almost 75% of the angle, with either PAS or elevated IOPs, but 
without cup disc ratio and visual field defect changes. The angle appears 
abnormal in structure (PAS) or function (elevated IOP). 
3. Primary angle-closure GLAUCOMA (PACG):  
         More than 270° of irido-trabecular touch contact plus elevated IOP plus 
optic nerve and visual field damage. Angle closure glaucoma manifests the 
criteria of closure above, plus demonstrable disc and/or visual field defect 
changes. The angle is usually abnormal in structure and function, with optic 
neuropathy. 
  
 
 
EPIDEMIOLOGY 
 In many populations, pupillary-block glaucoma is considerably less 
common than chronic open-angle glaucoma. However, there is a reversal in 
the ratio of angle-closure and open-angle glaucoma cases among Canadian 
Alaskan, and Greenland, Eskimos, with the pupil block glaucoma occurring 
in approximately 0.5% of the general population and in 2% to 3% of those 
older than 40 years of age, with a gender predilection for women. A similar 
finding  was noted in population studies from China, Singapore, Mongolia, 
and South India and a mixed ethnic group in South Africa, in which the 
prevalence of angle-closure glaucoma was 2.3%, compared with 1.5% for 
open-angle glaucoma, with the former showing a fourfold predilection for 
women. This prevalence of angle-closure glaucoma may be caused by a 
smaller corneal diameter and anterior chamber depth and a thicker, more 
anteriorly placed lens in affected individuals. A study among Alaskan 
Eskimos also showed a rapid increase in hyperopia after age 50 years, 
reaching 71.5% in persons older than 80 years of age . 
 Studies of the anterior chamber angle in various populations provide an 
impression of the prevalence of those at risk of developing pupillary-block 
glaucoma. In two large studies, 5% to 6% of those screened had suspicious 
anterior chamber angles, but only 0.64% to 1.1% were considered to have 
critically narrow angles. In a Vietnamese population residing in the United 
 
 
States, 8.5% had critically narrow angles and were considered at high risk for 
occlusion. 
RISK FACTORS 
 Several factors influence the configuration of the anterior chamber 
angle and the risk of developing PACG. 
Demographic features: 
Age 
 The depth and volume of the anterior chamber diminish with age, 
which may result from a thickening and forward displacement of the lens. 
Consequently, the percent of individuals with critically narrow angles is 
higher in older age groups.  
 The prevalence of pupillary-block glaucoma also increases with age, 
although it may peak at early age than that of chronic open-angle glaucoma. 
One study says that there is a incidence of  bimodal pattern, with the first 
peak at ages 53 to 58 years and the second at 63 to 70 years . However, it can 
occur at any age, including rare cases in childhood  
Race 
 The prevalence of primary angle-closure glaucoma (PACG) varies 
among different racial and ethnic groups. Among white populations in the 
United States and Europe, it is estimated at 0.1 %. Inuit populations from 
 
 
Arctic regions have the highest-known prevalence of PACG- 20- 40 times 
higher than that for whites.  
 The relative prevalence of PACG and POAG among Inuits is also the 
reverse of what is noted in white populations, with POAG being uncommon. 
 Estimates of the prevalence of PACG in Asian populations have varied 
considerably. Some of this  variability may be the result of differences in the 
definition used and in the design of the studies from which the estimates were 
derived. Another factor, however,is that Asian populations are not one 
homogeneous group. Available data suggest that most Asian population 
groups have a prevalence rate of PACG between that of whites and 
Inuits.Acute angle-closure glaucoma is relatively uncommon among blacks. 
However,chronic angle-closure glaucoma is much more common than 
initially believed.  
Gender:  
There is a statistically significant predominance of females in 
populations with pupillary-block glaucoma, which is probably caused by the 
shallower anterior chamber among women in general  
Refractive Error 
 The depth and volume of the anterior chamber are related to the degree 
of ametropia, with smaller dimensions occurring in hyperopes. However, the 
 
 
presence of myopia does not eliminate the possibility of angle-closure 
glaucoma because rare cases have been reported in such patients, possibly 
indicting a spherical or anteriorly displaced lens or an increase in corneal 
curvature. 
Family History 
 The potential for pupillary-block glaucoma is generally believed to be 
inherited . In one study, 20% of 95 relatives of angle-closure glaucoma 
patients were thought to have potentially occludable angles. However, aside 
from a few reported families in which many members developed angle-
closure glaucoma, the  presence of history of glaucoma in the family is not 
much useful in predicting development of a future acute angle- closure attack. 
Human leukocyte antigens were studied in 35 of angle-closure glaucoma 
patients, and no significant correlation was found . 
Systemic Disorders 
 One study demonstrated an inverse correlation between diabetes or 
presence of abnormal glucose-tolerance test(GTT) and the anterior chamber 
depth . The same investigators have suggested an increased prevalence of 
denervation supersensitivity to autonomic agonists in angle- closure 
glaucoma. 
 
 
 
 
FINDINGS DURING ROUTINE EXAMINATION 
 Certain observations during the course of a routine ocular examination 
can help to establish the potential for angle closure glaucoma. 
INTRAOCULAR PRESSURE 
 Unless the patient has angle closure at the time of the examination, the 
IOP is usually normal. One study, however, found a larger-than-normal 
amplitude in the diurnal IOP pattern curve, which was thought by 
investigators that it might have prognostic value. Tonography also 
characteristically reveals that normal aqueous outflow facility before or in 
between angle closure attacks, unless there is presence of peripheral anterior 
synechiae. 
Intraocular pressure 
 The Intra Ocular Pressure is usually calculated by evaluating the 
effective balance between aqueous out flow rate to the  rate of aqueous 
humour secretion. The aqueous outflow rate  is related to resistance offered 
by the outflow channels and the change in episcleral venous pressure(EVP). 
The aqueous outflow rate is usually directly proportional to the difference 
between the episcleral venous pressure. and intraocular pressure. 
Concept of normal intraocular pressure: 
 The Intraocular pressure distribution for the general population has a 
range group of 11–21 mm Hg. Eventhough there is no proper pathological 
 
 
reason, >21 mmHg is Taken to be the uppermost  limit of normal and The 
Intraocular pressure values  above this range is usually viewed with lot of 
suspicion.   
 This is because in certain patients, glaucomatous optic neuropathy 
damage occurs with lesser range of IOPs i.e, lesser than 21 mmHg which is 
referred to as normal-tension or normal-pressure glaucoma while in certain 
cases, there will be no glaucomatous damage even  with IOPs greater than 30 
mmHg  range(ocular hypertension). 
 Even though the actual levels of Intraocular pressure is important in the 
glaucomatous damage development, several factors also play a role in it. 
Fluctuation 
  The Normal range of IOP usually changes with the time, changes in 
heart rate, blood pressure increase or decrease and rate of respiration. The 
diurnal pattern of IOP fluctuation varies, with an usual pattern to be found 
higher in early morning followed by lower values in afternoon period and late 
evening. The Eyes of  normal subjects manifest a mean level diurnal pressure 
variation range of around 5 mmHg. Eyes with ocular hypertension or in eyes 
with glaucoma, it exhibits a wider variation. A single low normal IOP 
reading, particularly if taken during period of late afternoon, can be 
misleading and hence it is very much necessary to record multiple serial 
recordings at different periods of time in a day in a phasing pattern). In 
 
 
routine clinical practice the concept of phasing of IOP measurement in the 
morning time is ideal because Around 80% of patients have peak IOP levels 
between period of 8.00 a.m. and noon time. 
Tonometry 
Goldmann tonometry 
Principles 
 The mechanism of Goldmann applanation tonometry (GAT) is based 
on the Imbert–Fick principle,according to which for an ideal, dry, thin-walled 
sphere, the pressure (P) inside the sphere equals the force (F) necessary to 
flatten its surface divided by the area (A) of flattening (i.e. P = F/A). 
Theoretically, the capillary attraction of the tear meniscus  and the average 
corneal rigidity should cancel each other when the Area flattened has 
approximately 3.06 mm diameter contact surface of the Prism in Goldmann 
tonometer, which is applied to the cornea with a variable amount of 
measurable force from which the IOP is deduced. Disposable tonometer 
prisms and tonometer caps have been introduced to counter fears of infection 
from reusable prisms. 
Technique 
a. The patient is positioned at the slit-lamp with the forehead firmly 
against the headrest. 
 
 
b. After instilling topical anaesthetic and fluorescein is instilled in the 
conjunctiva. 
c. With the cobalt blue filter and the brightest beam projected obliquely at 
the prism, the prism is centred in front of the apex of the cornea. 
d. The dial is preset between 1 and 2 (i.e. 10–20 mmHg). 
e. The prism is advanced until it just touches the apex of the cornea. 
f. Viewing is switched to the ocular of the slit-lamp. 
g. A pattern of two semicircle mires can be observed as one mire above 
and one mire below the level of horizontal midline, which represent the 
fluorescein-stained tear film touching the upper and lower outer halves 
of the prism. 
h. The dial on the tonometer is rotated to align the inner margins of the 
semicircles. 
The observed reading on the tonometer dial is multiplied by 10, gives the 
correct IOP. 
Sources of error 
1. Overstaining with Excessive fluorescein can make themires very much 
thick and the observed radius to be very  small, when IOP will be 
overestimated, whereas insufficient fluorescein staining can make the 
semicircles to appear too thin and the radius to appear very large with 
underestimation  of consequent IOP. 
 
 
2. Pressure exerted on the globe while examining as well as the patient is 
squeezing the eyelids or due to restricted extra ocular muscles (e.g. thyroid 
myopathy) may result in an artificially high reading. 
3. Central corneal thickness (CCT). Calculations of  IOP by GAT assume 
that central corneal thickness is 520 microns, with minimal normal 
variation. If the cornea is thinner, underestimation of IOP may result, and 
if thicker an overestimation. Individuals with ocular hypertension tend to 
have corneas thicker than average, whereas those with normal-pressure 
glaucoma tend to have thinner corneas. Following refractive surgery 
procedures the cornea is both thinner and structurally altered such that IOP 
is likely to be underestimated. New methods of IOP measurement have 
been developed with the intention of reducing the effect of the various 
structural confounding variables. 
4. Corneal oedema may result in artificial lowering of IOP, presumably due 
to a boggy softening; notably the associated increased CCT seems to be 
more than offset. 
5. Astigmatism, if significant, may give distorted mires. If over three 
dioptres, the average reading of two can be taken with the prism rotated 
90° for the second, or preferably, the prism is rotated so that the red line 
on the tonometer housing is aligned with the prescription of the minus 
axis. 
 
 
6. Improper calibration of  tonometer can show a false reading. Hence it is 
very important to check this before each clinical session using the 
calibration arm supplied. 
7. Wide pulse pressure. It is normal for there to be a small oscillation in 
IOP in time with the rhythm of ocular perfusion. If this ‘pulse pressure’ is 
substantial, the mid-point is taken as the reading. 
8. Repeated readings over a short period can be associated with a 
reduction in IOP due to massaging effect on the eye. 
9. Other factors that may be associated with over-estimation of IOP include 
a tight collar and breath-holding, both of which obstruct venous return. 
EVALUATION OF PERIPHERAL ANTERIOR CHAMBER: 
 Anterior chamber depth and volume have also been shown to have 
diurnal variation, with lower values in the evening , although a correlation 
between diurnal variations of chamber depth and IOP is not clear. In any 
case, the most important step in the diagnosis of potential or manifest angle-
closure glaucoma is to evaluate the anterior chamber depth and especially the 
configuration of the anterior chamber angle. Although this is best 
accomplished by gonioscopy, there are preliminary screening measures that 
may be useful in some situations and techniques of quantifying the anterior 
chamber depth. 
 
 
 
PENLIGHT EXAMINATION 
 When a slit-lamp and goniolens are not available, the anterior chamber 
depth can be estimated with oblique penlight illumination across the surface 
of the iris. With the light shining from the temporal aspect of the eye, a 
relatively flat iris is  usually seen illuminated on the temporal side and nasal 
side of the pupil, whereas an iris that is wide and bowed forward has a 
shadow on the nasal side alone. 
 
 
 
 
 
 
 
SLIT-LAMP EXAMINATION 
 The central anterior chamber depth may be estimated during 
examination with the slit-lamp, and several techniques for quantitating this 
parameter have been proposed . However, the central anterior chamber depth 
corresponds weakly with the angle width, and the diagnostic parameter which 
is of greater diagnostic value for evaluating angle-closure glaucoma is the 
peripheral anterior chamber depth. Van Herick et al developed a technique for 
making this estimation with the slit-lamp by comparing the peripheral 
anterior chamber depth to the thickness of the adjacent cornea .This is 
commonly referred to as the van Herick technique. When examining, if the 
peripheral anterior chamber depth appears to be lesser than one fourth of the 
measured corneal thickness, the anterior chamber angle may be is at a chance 
of being occludable. 
 
 
 
 
 
 
 
 
 
GONIOSCOPY 
GONIOSCOPIC ASSESSMENT AND DOCUMENTATION 
 
 
 Gonioscopy should be carried out on a routine basis at the slightest 
suspicion of a glaucoma diagnosis. This examination is vital for the proper 
diagnosis and classification of glaucoma and hence for the specific treatment 
of the condition. 
 Gonioscopy requires the use of goniolenses due to the fact that, it is not 
possible to visualise the chamber angle directly throughcornea at an angle as 
the light beam radiating from the chamberangle will be totally internally 
reflected.  
 
 
 Furthermore, observation of Schlemm’s canal via the slit lamp is 
obstructed by the superficial scleral lip which covers the chamber  
GONIOLENSES AND THEIR USES 
 Gonioscopy requires the use of two different types of lenses for 
indirect gonioscopy of the individual eye; first a lens for a quick routine 
check – as well as an indentation gonioscopy (Posner’s)– then a more stable 
lens (Goldmann’s) for a detailed assessment without any real possibilities for 
indentation. 
 It is particularly important to observe this requirement , if the examiner 
is inexperienced. Also, optimum benefit from gonioscopy. 
 It is dependent on good patient co-operation, which is only obtained 
through a thorough explanation of the procedure to the patient and a gentle 
technique without undue movements of the gonioscopy lens. 
 While doing gonioscopy, the ophthalmologist should be able to identfy 
the angle structures and landmarks. The important pre-requisites for 
performing a proper  gonioscopy include a dim lit room and a short and 
thinner light beam to minimize the light which is entering the pupillary area 
that causes increased pupil constriction and which could falsely appear as to 
open the narrow angle and in turn prevents the correct identification of a 
occludable angle .The efficacy to look for scleral spur as well as the 
 
 
Schwalbe line is very important and a suitable gonioscopy technique to 
determine the correct position of the Schwalbe line(SL) is referred to as the 
parallelopiped technique. 
 The parallelopiped technique or corneal wedge, technique helps the 
examiner to evaluate the exact junction of the corneal trabecular meshwork. It 
is performed using a thin narrow slit beam and point focus, through which the 
examiner can see two linear reflections, of which one reflection can be 
visualised from outer corneal surface and its junction with the scleral surface  
and the other reflection from the inner corneal surface. Both the reflections 
meet at the level of Schwalbe line.  
 
  The scleral spur is a thin, pale coloured stripe which lies between the ciliary 
face and the pigmented trabecular meshwork(PTM).After confirming the 
 
 
landmarks, the clinician should examine the entire angle in an orderly 
manner. 
 When the peripheral anterior chamber depth appears shallow (i.e., less 
than one fourth of the corneal thickness by van Herick slit-lamp 
examination), gonioscopy of the angle is done preferably with a Zeiss four-
mirror lens or equivalent goniolens. If 270 degrees or more of the angle is 
closed (i.e., trabecular meshwork is not visible), it constitutes the definition of 
an occludable angle, and it is important to use indentation gonioscopy to 
determine whether the it is Synechial or appositional closure of angle. The 
patient should be examined in a dark room and with the use of a narrow slit 
beam to avoid pupil constriction and falsely opening the angle. The examiner 
also should take care to avoid extra pressure on the cornea so that the angle 
does not deepen artifactually. If necessary, the gonio mirror on the Goldmann 
three-mirror lens can be used to avoid artifactual deepening of the chamber 
angle. If the peripheral iris is prominent, or the iris is very convex and it is 
difficult to see angle structures, it is often helpful to have the patient look in 
the direction of the mirror being viewed so that a more accurate assessment of 
what angle structures are visible can be made. 
 Numerous grading systems have been suggested in an attempt to 
correlate gonioscopic appearance with the potential for angle-closure. Scheie 
proposed a system based on the extent of the anterior chamber angle 
 
 
structures that can be visualized. He observed a high risk of angle closure in 
eyes with grade III or IV angles. Shaffer suggested using the angular width of 
the angle recess as the criterion for grading the angle and attempted to 
correlate this with the potential for angle-closure . 
 Other investigators think that any single criterion does not fully 
describe the anterior chamber angle. Becker had found a method of 
combining anterior chamber angle width estimation and comparing the height 
of the iris insertion, whereas Spaeth recommended evaluation of 3 variables 
namely configuration of the peripheral iris , angular width of the angle recess, 
, and iris insertion. Whatever system the clinician prefers to use to document 
the appearance of the anterior chamber angle, it is important to pay close 
attention to these three aspects of the angle. One study proposed a relatively 
simple method for measurement of the distance from the iris insertion to 
Schwalbe's line using a reticule based in the slit-lamp ocular during 
gonioscopy. The investigators called this technique biometric gonioscopy and 
found that it correlated well with other measures of anterior chamber angle, 
showing a higher degree of interobserver reliability than conventional 
gonioscopy. Additional features of the angle should also be studied and 
documented, such as peripheral anterior synechiae and degrees or 
abnormalities in pigmentation. One study found that patients with narrow 
angles may have a predominance of trabecular meshwork pigmentation in the 
 
 
superior quadrant, rather than the more common inferior location, which the 
investigators thought might be caused by rubbing between the peripheral iris 
and the meshwork. 
GONIOLENSES 
 
 
 
NEWER TECHNIQUES : ULTRASOUND  BIOMICROSCOPY 
 Several newer forms of technology are being applied to evaluation of 
the anterior segment of the eye to more accurately quantify the anterior 
chamber depth and related dimensions. The use of high-frequency ultrasound, 
referred to as ultrasound biomicroscopy, allows definition of the relationships 
of the iris, posterior chamber, lens, zonules, and ciliary body.  
 This technique has potential value in understanding the mechanisms of 
glaucoma and in aiding the diagnosis of pupillary-block glaucoma, especially 
when the media is not clear. It may also be of value in identifying eyes with 
potentially occludable anterior chamber angles. It has been suggested that 
anterior chamber depth (ACD) measurement and the biometric calculation of 
the ratio of lens thickness to axial length can be used as a prognostic indicator 
of pupillary-block glaucoma. Ultrasound biomicroscopy has also been used to 
image the dynamic changes in anterior ocular structures during provocative 
testing in a dark room. 
 ACD measurement may also be carried out using the ultrasonic A-
scanning equipment normally used for cataract surgery biometry. It should, 
however, be stressed that an ultrasonic measurement determines the external 
value (including cornea). The “internal value” may then be found by 
subtracting the average cornea thickness of 0.5 mm, remembering that only 
 
 
one decimal is used with ACD measurement by the optical method. 
Therefore, it is important to specify whether the given measurement either 
includes or excludes the corneal thickness. 
 When using ultrasonic determination, the ultrasonic head must be in 
contact with cornea, which may lead to corneal indentation with the risk of 
underestimating the chamber depth. This may be avoided by using the new 
laser-based non-contact biometrical technique, precisely as with optical 
pachymetry. Thus, these two methods are the most precise. It should, 
however, be noted that the laser-based biometry also measures the “external 
ACD”, and that the corneal thickness must be subtracted, just as is the case 
with the ultrasonic method. 
 As previously stated, ACD determination is of great importance in the 
main classification of PAC with respect to differential diagnosis between 
pupil block conditioned PAC and the plateau iris form.  
As a general rule, pupil block conditioned PAC only occurs with 
values below 2.5 mm ACD (internal measurement) and predominantly with 
values ≤ 2.0 mm. Also, the prevalence rate significantly higher with lower 
ACD values – up to 85% below 1.5mm. This clear, inverse relationship to the 
prevalence of PAC with pupil block and thereby the degree of angle 
narrowness means that ACD measurement is the only method that enables a 
 
 
quantitative, indirect estimation of the size of the chamber angle. This makes 
the measurement a rational supplement to the subjective gonioscopic 
assessment of the narrowness of the chamber angle with the pupil block form 
of PAC (ref: Main classification and classification methods). The relationship 
between the axial chamber depth and the prevalence of angle-closure does 
not, however, exist with purely plateau iris PAC where the angle is narrow in 
spite of normal ACD(≥ 2.5 mm)12. This is used in the differential diagnosis 
between pupil block and plateau iris PAC. 
OPTIC DISC EVALUATION 
Careful assessment of optic disc is an essential and indispensible part 
of clinical evaluation of glaucoma.  
Optic nerve head is preferably examined by slit lamp biomicroscopy 
with 90D lens which offers a stereoscopic and a magnified view of the optic 
nerve head and retinal nerve fiber layer.  
VARIOUS OPHTHALMOSCOPIC SIGNS OF GLAUCOMATOUS 
OPTIC DISC DAMAGE  
General signs:  
Ø Large optic cup to disc ratio(>0.5:1)  
Ø Asymmetry of cups between eyes(>0.2)  
Ø Progressive enlargement of optic cup  
 
 
 
FOCAL SIGNS:  
NOTCHING OF NEURORETINAL RIM  
 Neuro retinal rim is often the first area to show changes in glaucoma 
.Normal NRR is uniformly pink in color indicating good vascular perfusion. 
Width of the neural rim tissue varies by quadrant and usually the inferior 
quadrant has the widest rim tissue with the superior portion second in width. 
The nasal tissue is slightly thinner than the superior tissue and the tissue in 
the temporal quadrant is the thinnest –  which follows the I-S-N-T Rule. This 
variation in rim sizes will cause large physiologic cups to appear elongated 
horizontally. Other focal signs include - 
· Vertical elongation of optic disc cup  
· Splinter hemorrhages 
· Laminar dot sign 
VASCULAR SIGNS  
Ø Over pass vessel phenomenon  
Ø Bayoneting of vessels  
Ø Nasalization of vessels  
Ø Baring of circumlinear vessels  
Peripapillary signs:  
Ø Nerve fiber layer loss (initial wedge defects to complete RNFL loss)  
Ø Peripapillary crescent  
 
 
Ø Splinter hemorrhages 
VISUAL FIELDS 
Glaucomatous visual field defects include the following: 
Ø generalized depression 
Ø nasal step 
Ø paracentral scotoma 
Ø arcuate or Bjerrums scotoma (Superior/ Inferior/ Double) 
Ø Advanced altitudinal defect  
Ø temporal wedge 
Visual field testing is a cornerstone in diagnosis of glaucoma. It is based 
on the ability of patient to identify a light stimulus on dull white background. 
One of the automated techniques currently being used is Humphrey 
automated perimetry. 
Criteria for glaucomatous abnormality in visual fields:  
Anderson has described the minimal criteria for diagnosing acquired 
glaucomatous damage which is summarized as:  
1. Glaucoma hemi field test (GHT) which is outside normal limits.  
2. A Cluster of 3 or more of non-edge points in 30-2(edge point in 24-2) 
in a area which is typical of glaucoma, which appear depressed on 
pattern deviation plot at a p< 5% level and  one of which is depressed 
at p<1% level on two consecutive fields.  
 
 
3. Abnormal corrected pattern standard deviation (CPSD) with p 
depressed below 5% level 
 
 
 
 
 
 
 
 
 
  
 
 
MANAGEMENT 
 Various modes of therapy are in use for different types of 
glaucoma. Since the disease was known to ophthalmologists, patients 
compliance in taking the drug, diurnal variations of this disease has 
prompted the ophthalmologist to look for a permanent cure. Drugs like 
pilocarpine and anticholine esterase drugs have their own side effects. 
 Different types of filtering procedures are advocated for open 
angle and closed angle glaucoma. Success rate was better when 
compared to medical treatment. Surgeon has to think twice before he 
undertakes the technique because of post-operative complications like 
postoperative hyphemas, shallow anterior chamber, lens opacities, 
malignant glaucoma, endophthalmitis etc. Surgery in cases of 
prodromal stages of angle closure glaucoma can lead to more 
immediate complications than the disease. 
 If a patient is glaucoma suspect, the ophthalmologist must decide 
whether to treat or simply to observe the patient. That decision usually 
depends on the surgeons judgement of amount of rise in IOP/of the 
patient is left untreated. Alternative "NON INVASIVE" therapy is 
found in form of "LASER Iridotomy" in eyes with angle closure 
glaucoma. 
 
 
Single intervention like iridotomy in primary angle closure glaucoma could 
obviate the need for further medical treatment. 
  Society is demanding more of physicians than ever before. In these 
days of cost containment and increased utilization of newer and better 
medical technique, it is prudent to reduce the use of medical resources by 
concentrating on procedures to cure or control the disease effectively. So that 
more resources and time can be directed towards patients whose condition is 
uncontrolled or imminent threat to vision. 
 The aim of the study is to assess the predictability of laser iridotomy as 
principal modality of intervention on various types of primary angle closure 
glaucoma. 
 
INTRODUCTION TO LASER IRIDOTOMY 
By last of the eighteenth century, the thermal effect of light 
focused through a magnifying glass had been used to burn a hole 
through paper. In 1916, Verhoef and Bell focused sunlight on the iris 
and retina. In 1958 McDonald and Light produced patent iridotomies 
using high-intensity radiant energy from a copper-located carbon arc, 
but lenticular opacities were a problem. In 1956, Meyer-Schwickerath 
first reported the creation of a patent iridotomy using the xenon arc 
photocoagulator. Hogan and Schwartz and Burns also produced patent 
 
 
openings in the iris, but their success was limited by corneal and 
lenticular damage caused by the large amounts of applied energy. 
The development of laser technology led to the use of monochromatic 
focused light in anterior segment surgery. Iridotomies made with 
pulsed ruby laser required less energy than previous methods, with 
both a shorter duration and lower amplitude of energy emission. In 
1973, Beckman and Sugan attempted without success to use the 
neodymium laser in human irides. 
 The development of the continuous wave argon laser led to a 
virtual revolution in the treatment of glaucoma . In 1973 Khuri created 
patent iridotomies in rabbits. The same year, Beckmann and Sugar 
reported success in humans but the opening were very small and closed 
with pigment. Others soon reported success in human eyes with angle 
closure glaucoma. 
 Difficulties in penetrating dark brown and blue irides were 
overcome by developments in techniques by Ritch and Podos, Ritch 
and Palmberg, Stetz et al, Hoskins and Pollack. Ease and convenience 
of the procedure for both the patient and surgeon and the paucity of 
severe complications due to invasive surgeries provided the impetus for 
its rapid acceptance. By the early 1980s, argon laser iridotomy had 
 
 
replaced incisional surgical iridotomy as the procedure of choice for 
angle-closure glaucoma. 
 More recently, the neodymium: YAG (Nd: YAG) laser which 
causes mechanical disruption of tissue, has been used safely and 
successfully to create iridotomies in both darkly and lightly pigmented 
irides. Because of its case of use, requiring less subtlety of techniques 
compared to the argon laser, it has become widely accepted. 
 
YAG Iridectomy created by focusing deep Into the  Iris stroma. Optical 
breakdown b produced, and the shock and acoustic waves cause the 
iridectomy to form 
 
 
.
 
INTRODUCTION Nd.YAG LASER: 
 The laser is a source of coherent single frequency,high brightness 
and low divergence light beam. In ophthalmic application two of these 
parameters ,high brightness and low divergence are important. It is the 
combination of these parameters that allows extremely high intensity of 
light to be focussed into a small region causing nonlinear absorption of 
light by usually transparent tissue and allows the Nd.YAG laser to 
disrupt these tissue non invisibly. 
All lasers have three basic elements: 
v A laser medium 
v A source of excitation or pumping of laser medium 
 
 
v Feedback of the light through the laser medium ( usually with  
mirrors ) 
 The laser medium may be solid or liquid. The key to the 
operation of lasers is elicitation of electrons atoms and molecules to 
leave the orbital which are more energetic than the normal or ground 
state levels. 
 A rare earth element NEODYMIUM is the lasing medium of the 
Nd.YAG laser, Atoms of Neodymium are doped into a synthetic crystal 
of YAG which is formed into a cylindrical rod ( YAG - Yttrium, 
Aluminium, Garnet). 
 The solid structure has broad absorption bands which allow the 
light from a flash lamp concentrated onto the rod to excite the 
Neodymium atoms which are normally in the lowest energy level or 
ground stage 
 If a sufficient amount of Neodymium atoms absorb the pumping 
light, these will have higher energy levels atoms than those are in 
lower energy level atoms and a population inversion. 
YAG-laser iridotomy eliminates the pressure difference between the 
anterior and posterior chambers caused by the abnormal pupil block and 
thereby flattens the iris. In this way, the chamber angle is opened provided 
there are no PAS present  
 
 
 
WHEN TO PERFORM A PROPHYLACTIC PERIPHERAL 
IRIDOTOMY 
 Having decided that a patient has suspiciously narrow anterior chamber 
angles, the physician is faced with a difficult decision. If it could be predicted 
that the patient would eventually have an attack of angle-closure glaucoma, 
the appropriate course in most cases would be prophylactic peripheral 
iridotomies. The results of one study suggest that optic nerve damage occurs 
in the early period after IOP increases, supporting the value of detecting 
potentially occludable angles and performing prophylactic surgery before an 
attack. 
 
 
 If the angle is deemed occludable (i.e., 180 degrees or more of 
appositional angle closure), prophylactic peripheral iridotomy is warranted. 
The fellow eye should also be examined, and if deemed occludable, our 
recommendation is to proceed with iridotomy at the same sitting. 
Provocative Tests 
 Historically, some surgeons used tests to provoke pupillary-block 
glaucoma when attempting to identify patients for whom treatment should be 
recommended. These tests included the prone test, the darkroom test, the 
prone darkroom test, and pharmacologic dilation of the pupil.  
Most ophthalmologists question the clinical value of any provocative 
test for angle-closure glaucoma because the false-positive and false-negative 
rates of such tests are high. In one study of 129 persons with suspected angle-
closure glaucoma who underwent refraction,gonioscopy, pachymetry, 
ultrasound biomicroscopy(UBM), and an angle-closure provocative test, it 
was concluded that none of the test factors analyzed indicated  higher 
sensitivity or positive predictive value in detecting the eyes that developed 
angle closure component later. Careful gonioscopic examination put into the 
context of available historical and clinical information has largely replaced 
the use of provocative tests to make management decisions regarding the 
development of angle-closure glaucoma. 
 
 
INDICATIONS 
Ø Imminent PAC with pupil block groups I and III 
Ø Acute/subacute PAC with pupil block groups I and III 
Ø Chronic PAC with pupil block groups I and III 
• Latent PAC glaucoma with pupil block groups I and III (In manifest PAC 
glaucoma with pupil block (I) and mixed group (III) where PAS are present 
in > 80-90% of the angle circumference, iridotomy will not have a pressure 
reducing effect, possibly even the opposite)  
CONTRAINDICATIONS 
Ø Terminal manifest PAC glaucoma (C/D ratio 0.9 and/or tunnel vision) 
with pupil block groups I and III due to the risk of post-laser increase 
in pressure. 
POST-TREATMENT: 
Local steroid x 3-4 daily for 3-5 days 
Pressure measurement after 1-3 days. 
Especially in cases with PAC mixed group (group III), gonioscopy 
should be repeated the following day with regard to possible plateau iris with 
continued occludable angle representing an indication for iridoplasty. 
 
 
 COMPLICATIONS: 
· Haemorrhage from iris. 
· IOP increase (within 3 hours post-laser). 
· Minor iritis and posterior synechiae. 
· Closure of iridotomy. 
· Lens damage 
· Corneal laser marks. 
  
 
 
TRABECULECTOMY 
 Trabeculectomy is the surgery done for the treatment of glaucoma to 
reduce and relieve the intraocular pressure (IOP) by removing a part of the 
eye's trabecular meshwork along with the adjacent structures and thereby 
creating a fistula for aqueous outflow. 
INDICATION FOR TRABECULECTOMY:  
 Uncontrolled IOP despite maximum tolerable medical therapy, when 
cataract is insignificant  
PROCEDURE  
 A fornix-based conjunctival flap is created and the subconjunctival bed 
is treated with 0.02% mitomycin C soaked sponge for 3 minutes. This 
antifibrotic agent prevents failure of the filtering bleb from getting fibrosed 
and scarred by inhibiting the fibroblastic proliferation. A partial thickness 
scleral flap with base of the flap at the corneo-scleral junction is made in the 
after gentle cauterization of the flap site. Paracentesis is done after which a 
window is created under the scleral flap with a Kelly’s punch to remove a 
part of the scleral tissue, the Schlemm's canal and  part of the trabecular 
meshwork to gain access to the anterior chamber. Peripheral iridectomy is 
done through that window. This iridectomy will avoid and  prevent blockage 
of the sclerostomy ostium in the future. The scleral flap made is sutured back 
with adequate tightness in place with 3 sutures, 2 releasable sutures on sides 
 
 
of flap and one apical fixed non-absorbable suture. The conjunctiva is then 
apposed  in a water-tight fashion with 9-0 vicryl suture at the end of the 
procedure.  
FUNCTIONING OF TRABECULECTOMY:  
 The basic mechanism is the creation of an opening, or fistula, at limbus 
which allows drainage of the aqueous humor from the anterior chamber, and 
there by bypassing the pathological obstruction caused to outflow. The 
aqueous flows directly or indirectly into subconjunctival space and is then 
gets absorbed in the episcleral vessels.  
ADVANTAGE:  
1. Less post operative inflammation due to minimal intraocular 
manipulation  
Disadvantages:  
1. Delays visual recovery due to two stage procedure.  
2. Cataract surgery in presence of a functioning filtering bleb causes the 
bleb to fail in 30 % of cases. It is also associated with loss of long term 
intraocular pressure control.  
3. A trabeculectomy in isolation is also likely to accelerate cataract 
formation. 
 
 
 
 
REVIEW OF LITERATURE 
Ø Zainah Alsagoff et al1 in his study did retrospective analysis of180 
patients who underwent Laser peripheral Iridotomy for a period of 4 years 
and a total of 83 eyes in 65 patients were diagnosed to have PACG. All 
study eyes underwent laser peripheral iridotomy (LPI). They classified the 
study patients into two groups of which consisted of patients with previous 
history of an acute angle closure attack and those patients with no previous 
acute episode. At the end of the study they found that of the 83 eyes, only 
5 of the eyes (6%) did not require any treatment after LPI in the long term. 
In group with previous history of an acute angle closure attack (35 eyes), 
all of the eyes required further antiglaucoma medications. 22 of the eyes 
(62.9%) in that group eventually underwent filtering surgery at a mean of 
7.3 months. In group without any previous acute episode (48 eyes), 43 of 
the eyes (89.6%) underwent further medical therapy, of which 22 of the 
eyes (45.8%) eventually underwent filtering surgery at a mean of 18.4 
months. 
Ø Mohamad Rosman et al2 in his study retrospectively analysed the 
treatment outcome based on IOP in51 patients (total 80 eyes) who were 
diagnosed with CACG with glaucomatous optic nerve head and visual 
field damage and had undergone laser peripheral iridotomy for a period of 
4 years were analyzed and compared with 65 Asian patients (total 83 eyes) 
 
 
from a another hospital who were studied during the same period. They 
concluded that despite the presence of a patent Laser PI, most of the eyes 
with CACG who presented with elevated Intra ocular pressure and both 
glaucomatous disc and visual field defect damage in both of the 
populations required further treatment for IOP control.  
Ø J.F Salmon et al3 in his study Retrospectively analyzed 52 patients (78 
eyes) with CACG who has undergone YAG PI with a Follow up period of 
around  22 months. The Intraocular pressure levels was the main outcome 
measure and IOP <22mmHg  was observed in 7 (9%) eyes without any 
additional Treatment and 40 (51.3%) eyes with  additional antiglaucoma 
medications,At last follow up visit, IOP between 22-24mmHg in 8 
patients. Trabeculectomy was done in 23 eyes (29.1%). It was concluded 
that, Eyes with IOP >35mmHg, >3 quadrants of angle closure, and  CDR 
>0.6, more likely to undergo Trabeculectomy. Linear discriminant 
analysis of ocular findings at presentation showed that among eyes which 
underwent Trabeculectomy, it could have been predicted only in 78%, and 
rest 36% could have got controlled with medications without unnecessary 
Trabeculectomy. 
Ø Winifred P Nolan4 et al in his study retrospectively analysed patients with 
occludable drainage angles in two glaucoma prevalence surveys who  
were treated with YAG laser iridotomy at the time of diagnosis who were 
 
 
re-evaluated after 3 years. The intraocular pressure (IOP), visual acuity, 
iridotomy patency, and gonioscopy findings were evaluated. On final 
evaluation of 164 eyes of 98 subjects who were examined, patent PI was 
found in around 98.1% (157/160) of eyes that had not undergone surgery.. 
Only Iridotomy cases failed in 3% eyes with narrow drainage angles and 
either presence of peripheral anterior synechiae or increased IOP, but 
normal cup disc ratio and no visual field defects. But, in eyes with already 
established glaucomatous optic neuropathy at , only iridotomy failed in 
almost 47%. And none of the eyes with occludable angles which 
underwent YAG PI and were found to be normal otherwise, developed 
glaucomatous optic neuropathy or angle closure attack in the follow up 
period. 
Ø Ching-Hsi Hsiao et al5 in his study retrospectively analyzed the case 
records of 138 patients (total 231 eyes) who had undergone Nd:YAG laser 
iridotomy in a hospital during a period of 3 years. The mean follow-up 
period was 51 months. On evaluation, of the eyes treated, around 10.8% 
were treated for acute angle-closure glaucoma and 25.1% were treated for 
chronic angle-closure glaucoma; and most of the eyes with occludable 
angles (64.1%) underwent prophylactic iridotomy.  Intraocular pressure 
(IOP) was found to be decreased in most eyes after Nd:YAG laser 
iridotomy and around 10 eyes alone further required filtration surgery. 
 
 
Visual acuity remained unchanged in around 97.9% of all eyes during the 
6-month follow up visit. 8 of the 14 eyes with peripheral anterior 
synechiae (PAS) > 270° underwent further filtration surgery to control the 
IOP.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIMS AND OBJECTIVES 
To study the long-term clinical course, outcome & efficacy of  
treatment in primary angle closure glaucoma affected patients. 
OBJECTIVES: 
1. To assess the long term results of Nd:YAG laser iridotomy alone and 
Trabeculectomy post Nd-YAG laser iridotomy  in the treatment of 
patients diagnosed with primary angle-closure glaucoma 
2. To evaluate the role of gonioscopy in predicting the outcome after 
Nd:YAG laser iridotomy and trabeculectomy post LPI 
3. To analyze the functional outcome of procedure based on IOP ie. How 
many of the patients require further medical/Surgical management after 
LPI. 
PRIMARY OUTCOME: 
 Change in intra ocular pressure (IOP) after laser PI and 
trabeculectomy during the study period. 
 
 
 
 
 
SECONDARY OUTCOME: 
1. Change in gonioscopy findings, cup to disc ratio, visual acuity, visual 
fields after laser PI and trabeculectomy after laser PI during the study 
period. 
2. Long term medical and surgical outcome in the treatment of PACG. 
 
 
 
  
 
 
MATERIALS AND METHODS: 
STUDY DESIGN: 
Hospital based prospective observational study. 
SOURCE OF DATA: 
Glaucoma Services, Aravind Eye Hospital, Madurai. 
STUDY SUBJECTS : 
Patients who are diagnosed with primary angle-closure glaucoma and 
has undergone YAG PI from July 2013 to September 2013, will be enrolled 
for the study. Consent was obtained from all patients. Patient will be 
followed up till July 2015 
SAMPLE SIZE CALCULATION AND JUSTIFICATION BASED ON 
PREVIOUS STUDY: 
  A sample size of 40 patients will be enrolled in the study to prove 
whether intraocular pressure has decreased or come to normal level after 
laser iridotomy in patient with primary angle closure glaucoma.  IOP was 
measured for pre-op and 6month after LPI in pilot study with 20 patients.  
Mean(SD) of IOP in pre Laser PI and 6 month post LPI are 30(15) and 
20(10) respectively, with the assumption of power 80% and 5% level of 
significance are used to calculate sample size.   
 
 
STUDY PERIOD : 
July 2013 to July 2015 
INCLUSION CRITERIA: 
Ø The presence of glaucomatous optic neuropathy with closed angle* 
on indentation gonioscopy, elevated IOP and corresponding 
reproducible visual field loss as per HFA who had undergone YAG 
PI. 
Ø Greater than 270° of irido-trabecular contact with or without evidence 
of PAS in any part of the angle 
Ø Among the study population, Patients of who already had YAG PI 
done and those who had undergone trabeculectomy alone eventually 
in the course of treatment during the study period. 
EXCLUSION CRITERIA: 
Ø Primary angle closure/ PAC suspect with Occludable angles with no 
significant glaucomatous disc changes or field defects  
Ø Acute angle closure attack with high IOP, unless they showed 
evidence of optic nerve damage  
Ø Cases of secondary angle closure such as neovascularization of the 
iris, uveitis, trauma, lens intumescence, or subluxation were excluded. 
 
 
METHODOLOGY: 
PRE OPERATIVE DATA COLLECTION: 
Preliminary data was collected for all patients which included age , 
sex, type of glaucoma, pre opeartive medications, visual acuity ,visual fields 
by Humprey Automated Perimetry (24-2), IOP by applanation tonometry, 
gonioscopy, anterior segment examination with slit lamp and fundus 
evaluation by slit lamp biomicroscopy with 90 diopter lens. 
Data being collected include  
Ø Demographic data 
Ø Medical data 
Ø preoperative ocular data 
Ø The LPI was procedure was performed using VISULAS YAG-II Plus 
Laser machine - Nd YAG (1064nm) in all study subjects and an 
Abraham Lens is used to perform the procedure  
· Location 
· Energy: 3-8 mJ per shot 
· 1-3 pulses per shot 
· PI size-around 300-500 microns 
 
 
POST-LPI PROTOCOL:  
1. Topical Brimonidine is applied to subjected eye. 
2. Patient is given prescription of Topical Antibiotic+Steroids   QID for 
1 week and 2 times a day for 1 week in tapering dose.  
3. Patient is asked to review after 2 weeks. 
Post operative ocular data is collected as follows 
v IOP during the follow-up period; 
v Antiglaucoma treatment required (if any), including the time of 
commencing treatment and the type of treatment; 
v Surgery required (if any), including the indication, timing, and type of 
surgery; 
TRABECULECTOMY SURGERY  
The surgery was performed under local anaesthesia. A fornix-based 
conjunctival flap was created and the wound bed was treated with 0.02% 
mitomycin C soaked sponge for 3 minutes. This antifibrotic agent prevents 
failure of the filtering bleb from scarring by inhibiting fibroblastic 
proliferation. A partial thickness flap with its base at the corneoscleral 
junction was then made in the sclera after careful cauterization of the flap 
area, paracentesis is done then a window opening was created under the 
 
 
flap. Kelly’s punch was used to remove a portion of the sclera, Schlemm's 
canal and the trabecular meshwork. Peripheral iridectomy was done through 
that window. This iridectomy would prevent future blockage of the 
sclerostomy. The scleral flap was then sutured with adequate tightness back 
in place with 3 sutures, 2 releasable sutures on sides of flap and one apical 
fixed non-absorbable suture. The conjunctiva was closed in a watertight 
fashion with 9-0 vicryl suture at the end of the procedure. 
FOLLOW UP:       
  1st visit at 2 weeks 
  2nd visit at 3 months   
  3rd visit at 6 months   
  4th visit at 1 year 
  Last follow up visit within 2 years. 
 (At each visit following Investigations were recorded) 
1. Visual acuity:(BCVA) 
2. Slit lamp biomicroscopy 
3. Intra ocular pressure 
4. Fundus- Cup disk Ratio (Preop, 3months, 6 months) 
 
 
5. Gonioscopy (Preop and 3 months) 
HFA- Preop and 6 months/S.O.S 
STATISTICAL METHODS TO BE EMPLOYED: 
Mean (SD) or Frequency (Percentage) was used to describe summary 
information.  Student’s t-test or Mann-whitney U test was used to assess the 
difference of continuous variable.  Chi-square test was used to assess the 
association between categorical data.  P-value less than 0.05 considered as 
statistically significant.  All statistical analysis was done by STATA 11.1 
(Texas, USA). 
 
 
 
 
 
 
 
 
 AGE 
In our study, the mean age (SD) among patients 
PACG who had undergone YAG PI is 55.05(9.41) years and it ranges from 
38 years to 74 years 
GENDER 
We found equal Male and Female ratio in our study. Among the total 
40 patients, 21 patients were males, which comprised 52.5%.The female 
population represented  47.5% of the total number of  patients.
Gender 
Male 
Female 
Total 
Female, 47.
5%
Gender distribution
 
RESULTS 
presenting with 
 
N % 
21 52.5 
19 47.5 
40 100.0 
 
 
Male, 52.5
%
 YAG PI ENERGY 
Almost 51 eyes (63.75%) required a total energy level of 50
achieve a patent iridotomy 
Total  Energy level
<50mJ 
50-60mJ 
>60mJ 
Total 
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 n (no. of eyes) % 
5 6.25 
51 63.75 
24 30.0 
80 100 
>60 mJ
24
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LPI COMPLICATIONS  (Only for eyes which required filtration  
surgery) 
The complications caused during YAG PI procedure was 
predominantly mild Uveitis/iritis in the entire sample group with similar 
finding in 23 eyes of the total 30 eyes which required filtration  surgery after 
LPI. 
Complications n % 
No complication 7 23.3 
Mild Uveitis/ Iritis 23 76.7 
Total 30 100 
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VISUAL ACUITY 
  The visual acuity of all patients who had undergone YAG PI with or 
without trabeculectomy  surgery were converted into LogMAR units for 
comparison in our study. The median presenting visual acuity was 0.18 at 
time of presentation, which worsened to 0.30 after an year& till last follow 
up which was statistically significant (p value <0.001). 
BCVA 
Median 
(Snellen’s 
equivalent) 
Min - Max p-value 
Pre-op  0.18(6/9) 0 – 3.2 - 
2 weeks 0.18(6/9) 0 – 3.2 0.157 
3 months 0.24(6/12) 0 – 3.2 0.083 
6 months 0.30(6/12) 0 – 3.2 0.0002 
1 year 0.30(6/12) 0 – 3.2 <0.001 
Last follow up 0.30(6/12) 0 – 3.2 <0.001 
 
We also observed that among the patients under study. 50 eyes of 80 
who had undergone YAG PI and did not require any filtration surgery had 
no significant deterioration of visual acuity in the follow up period. While, 
the. 30 eyes of 80 who had undergone YAG PI and also required 
trabeculectomy  had almost  significant deterioration of visual acuity in the 
follow up period (0.39 to 0.48 with P value of 0.008).  
 
 
BCVA n (eyes) Median Min - Max P-value 
Overall 
      Before YAG PI 
      After YAG PI 
 
80 
80 
 
0.18(6/9) 
0.18(6/9) 
 
0 – 3.2 
0 – 3.2  
 
0.172 
Patient eyes which did not undergo Trabeculectomy 
 
YAG PI 
    Before YAG PI 
    After YAG PI 
 
50 
50 
 
0.18(6/9) 
0.18(6/9) 
 
0 – 3.2 
0 – 3.2  
 
0.173 
Patient eyes which underwent Trabeculectomy 
YAG PI(Trab 
group) 
    Before YAG PI 
    After YAG PI 
 
30 
30 
 
0.39(6/18) 
0.39(6/18) 
 
0 – 1.48 
0 – 1.48 
 
* 
Trabeculectomy 
    Before Trab 
    After Trab 
 
30 
30 
 
0.39(6/18) 
0.48(6/18) 
 
0 – 1.48 
0 – 1.48  
 
0.008 
 
* VA values are same in before and after YAG PI 
 
 Intra Ocular Pressure
IOP 
Pre-op  30.21(11.68)
2 weeks 23.52(7.14)
3 months 20.74(5.45)
6 months 18.65(4.86)
1 year 17.74(4.11)
Last follow up 17.74(4.11)
 
In our study we noted that, the Mean Preop YAG PI IOP was 
30.21(11.68) which declined to a mean IOP of 17.74 in last 
undergoing YAG PI, irrespective of patients who required additional 
medications or additional filtration surgery which was statis
significant ( p<0.001). 
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We also observed that among the patients under study. 50 eyes of 80 who 
had undergone YAG PI and did not require any filtration surgery had 
decrease in IOP in the follow up period (25.88 to 20.46 with p value  
<0.001). While, the. 30 eyes of 80 who had undergone YAG PI and also 
required trabeculectomy also  had decrease in IOP in the follow up period 
(27.53 to 17.00  with  p value <0.001). 
IOP n (eyes) Mean(SD) Min – Max P-value 
Overall 
      Before YAG PI 
      After YAG PI 
 
80 
80 
 
30.21(11.68) 
23.53(7.14) 
 
21 – 64 
14 – 51  
 
<0.001 
Patient eyes which did not undergo Trabeculectomy 
YAG PI 
    Before YAG PI 
    After YAG PI 
 
50 
50 
 
25.88(8.99) 
20.46(4.51) 
 
21 – 56 
18 – 38 
 
<0.001 
Patient eyes which underwent Trabeculectomy 
YAG PI(Trab group) 
    Before YAG PI 
    After YAG PI 
 
30 
30 
 
37.43(12.21) 
28.63(7.83) 
 
22 – 64 
20 – 51 
 
0.0002 
Trabeculectomy 
    Before Trab 
    After Trab 
 
30 
30 
 
27.53(7.16) 
17.00(2.15) 
 
20 – 51 
10 – 19  
 
<0.001 
 
 
 
GONIOSCOPY 
Among Gonioscopic findings at time of presentation in 80 eyes, 35 
eyes (43.7)% had >270 degree of angle closure without Peripheral anterior 
synechiae, around 45 eyes(56.3)% had >270 degree of angle closure with 
Peripheral anterior synechiae. 
On follow up visit in 3 months, of the 80 eyes which had undergone 
YAG PI ,  39 eyes (48.7%) had narrow angles with PAS, 35 eyes(43.7%) 
had angles narrow angles with PAS, open on indentation, and 6 eyes(7.5%) 
had narrow angles with Patent ostium. 
Gonio n (n=80) % 
Pre-op (Before YAG PI) 
<270 
> 270-PAS 
>270+PAS 
 
- 
35 
45 
 
0 
43.7 
56.3 
3monthfollow up 
Narrow without PAS 
Narrow with PAS 
Open/Narrow  
   (with patent Ostium) 
 
35 
35 
10 
 
43.7 
43.7 
12.5 
 
 
 
VISUAL FIELDS 
On evaluation of Visual field defects, we found that 34 patients 
(42.5%) had superior arcuate scotoma,  32 patients (40%) was having 
double arcuate scotoma and 10 patients (12.5%) had advanced or end stage 
field defects. And at 6 months follow up period, 33 patients (41.5%) had 
superior arcuate scotoma and 34 patients (42.5%), had double arcuate 
scotoma. While the patients with advanced or end stage field defects did not 
show any change. 
Visual fields Pre-op 6 months 
Nasal step/ Temporal wedge - - 
Superior arcuate defect  34(42.5) 33(41.25) 
Inferior arcuate defect 5(6.2) 4(5.0) 
Double arcuate defect 32(40.0) 34(42.5) 
End stage, complete field loss 10(12.5) 10(12.5) 
Total 80 80 
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CUP TO DISC RATIO (CDR) 
The Vertical cup disc ratio at initial presentation had a mean value of 
0.73 (0.13) which did not show any significant change in the 3 month follow 
up, while it worsened to 0.74 in the 6 month follow up period which was 
significant. 
CDR Mean(SD) Min – Max P-value 
Pre-op 0.73(0.13) 0.30 – 0.95 - 
3 month 0.73(0.13) 0.30 – 0.95 >0.999 
6 month 0.74(0.13) 0.30 – 0.95 0.0001 
 
Number of medications 
In our study, None of the patients were using any antiglaucoma 
medications before performing YAG PI and we observed that, the Number 
of antiglaucoma medications prescribed after YAG PI had a mean of 1.23 at 
2 weeks follow upperiod, which increased to 1.49 at 3 month follow up , but 
it reduced to 1.20 and 1.15 at the 6 month, 1 year  and last follow up period 
respectively. 
 
 
  
Number of medications
2 weeks 
3 month 
6 month 
1 year 
Last follow up 
 
 
Two 
medication, 32
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medication, 2.
Number of medications  at 1year
 
 Mean(SD) Min – Max
1.23(0.64) 0 – 3 
1.49(0.79) 0 – 3 
1.20(0.77) 0 – 3 
1.15(0.81) 0 – 3 
1.15(0.81) 0 – 3 
No 
medication, 23
%
one 
medication, 41
.9%
Three 
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We also observed that among the patients under study, almost all 
patients required antiglaucoma medications after YAG PI. in the 50 eyes of 
80 who had undergone -YAG PI and did not require any filtration surgery  
required antiglaucoma medications of mean value 1.06. While, the. 30 eyes 
of 80 who had undergone YAG PI and also required trabeculectomy  
required antiglaucoma medications of mean value 1.70 before 
trabeculectomy, which decreased to 0.71 after trabeculectomy in the follow 
up period with a  p value  <0.001 which was statistically significant. 
Number of 
Medication 
n (eyes) Mean(SD) Min - Max P-value 
Overall 
      Before YAG PI 
      After YAG PI 
 
- 
80 
 
- 
1.23(0.64) 
 
- 
0 – 3 
 
- 
Patient eyes which did not undergo Trabeculectomy 
YAG PI 
    Before YAG PI 
    After YAG PI 
 
- 
50 
 
- 
1.06(0.62) 
 
- 
0 – 3 
 
- 
Patient eyes which underwent Trabeculectomy 
YAG PI(Trab group) 
    Before YAG PI 
    After YAG PI 
 
- 
30 
 
- 
1.50(0.57) 
 
- 
1 – 3 
 
- 
Trabeculectomy 
    Before Trab 
    After Trab 
 
30 
30 
 
1.7(0.60) 
0.71(0.60) 
 
1 – 3 
0 – 2 
 
<0.0001 
 
 
NEED FOR ANTIGLAUCOMA MEDICATIONS 
Number of 
medications 
2 week 3 month 6 month 1 year 
Last 
follow up 
0 - 2(2.5) 8(10) 10(12.5) 10(12.5) 
1 53(66.25) 30(37.5) 38(47.5) 34(42.5) 34(42.5) 
2 25(31.25) 41(51.25) 30(37.5) 28(35) 28(35) 
3 2(2.5) 7(8.75) 4(5) 8(10) 8(10) 
 
  
 NEED FOR FILTRATION SURGERY
Of the 80 eyes, which had undergone YAG PI, around 30 eyes 
(37.5%) eventually required Trabeculectomy surgery and almost 50 
not require any filtration procedure for IOP control.
patients who did not undergo trabeculectomy underwent 
Phacoemulsification with IOL surgery during our study period for 
coexisting cataract. 
Surgery 
Trabeculectomy 
No filtration surgery
Total 
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 Among them, three 
n % 
30 37.5 
 50 62.5 
80 100 
No surgery
37.5
62.5
eyes did 
 
 
 
TIMING OF TRABECULECTOMY POST LASER PERIPHERAL 
IRIDECTOMY 
Of the 30 eyes which required trabeculectomy post YAG PI, 23 eyes 
(76.7%) required trabeculectomy  within a duration of 1-6 months post LPI, 
5 eyes (16.7%) within 1 month and 2 eyes(6.6%) after 6 months-1 year. 
Duration n (no. of eyes) % 
<=1 month 5 16.7 
>1 – 6 month 23 76.7 
>6 – 12 month 2 6.6 
Total 30 100 
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Correlation between Timing of trabeculectomy post Laser Peripheral 
Iridectomy and preoperative factors: Cup disc ratio, IOP, and  
Gonioscopy. 
Time: YAG 
PI to Trab 
n 
CDR, 
Mean(SD) 
IOP, 
Mean(SD) 
Preop Gonio, n (%) 
Before trab 
>270 with 
PAS 
>270 
No PAS 
<= 1month 5 0.82(0.08) 34.40(12.34) 5(100.0) - 
>1 -6months 23 0.81(0.08) 26.39(5.12) 23(100.0) - 
> 6months 2 0.70(0.14) 23.50(0.71) 1(50.0) 1(50) 
 
MEDICAL OUTCOME 
To summarize, we found that, only 11 eyes of 30 (36.6%) who 
underwent trabeculectomy after YAG PI did not require any additional 
antiglaucoma medications and had no long term IOP rise in the follow up 
period. and additional antiglaucoma medications after YAG PI was needed 
in all 50 patients (100%) and additional antiglaucoma medications after 
Trabeculectomy was needed in 19 of 30 patients (63.4%) 
 
 
 
Eyes N % 
Post YAG PI 50 
YAG PI without medication 0 0 
YAG PI with additional medication 50 100 
Post Trabeculectomy 30 
Trabeculectomy  with no additional 
medication 
11 36.6 
Trabeculectomy with additional 
medication 
19 63.4 
 
SURGICAL OUTCOME 
To summarize, based on our primary outcome, i.e Intra ocular 
pressure, A success is defined as ability to lower the IOP (IOP<=21) and 
failure is inability to lower IOP (IOP>21).  And Along with medications, 
YAG PI alone was found to be successful in 39 of 50 patients (78%) and 
additional Trabeculectomy after YAG PI  was  found to be successful in 29 
of 30 patients (96.7%) 
 Surgical outcome
YAG PI only 
      Success 
      Failure 
Trabeculotomy 
      Success 
      Failure 
Overall (Final IOP) 
      Success 
      Failure 
Success –
Failure, 3.7%
Surgical outcome 
 
 n % 
 
39 
11 
 
78.0 
22.0 
 
29 
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96.7 
3.3 
 
77 
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96.3 
3.7 
 
 IOP <=21, Failure – IOP >21 
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DISCUSSION 
AGE DISTRIBUTION 
In our study, the mean age (SD) among patients presenting with 
PACG who had undergone YAG PI is 55.05(9.41) years and it ranges from 
38 years to 74 years 
This age group was slightly of wider age group in comparison with 
the group selected in the study byRosman M et al and Alsagoff Z et al. 
While Age range of Patients in the study by Ching-Hsi Hsiao et aland 
Salmon et al were almost similar to our group. 
 
 
 
 
 
Study Age distribution Mean Age group 
Our study 38 - 74 years 55.05 ± (9.41) years 
Rosman M et al 59- 77 years 68.2 ± 9.2 years 
Alsagoff Z et al 54–72 years 60.8 ± 9.0 years 
Ching-Hsi Hsiao et al5 40-83 years 62 ± 11 years 
Salmon et al 56- 68 years 64.3 years 
 
 
SEX DISTRIBUTION 
We found equal Male and Female ratio in our study. Among the total 
40 patients, 21 patients were males, which comprised 52.5%.The female 
population represented 47.5% of the total number of  patients. Our study 
group was almost similar to the study group by Rosman M et al. All other 
study groups had a female preponderance. 
 
YAG PI ENERGY 
In our The Mean Laser PI energy required to achieve a patent 
iridotomy  was in the range of  50-60mJ which is comparable to the study 
by Alsagoff Z et al where the energy used was in the range of 15- 50 mJand 
study by Ching-HsiHsiao et al where the mean energy was 65.9 ± 83.6 mJ. 
 
STUDY Male Female 
Our study 21 (52.5%) 19 (47.5%) 
Rosman M et al 22 (43.1%) 29 (56.9%) 
Alsagoff Z et al  26 (40%) 39 (60%) 
Ching-Hsi Hsiao et al5 30 (21.7%) 108 (78.2%) 
Salmon et al 9 (17%) 43 (82.7%) 
Winfred P Nolan et al 28 (28.5%) 70 (71.4%) 
 
 
LPI COMPLICATIONS (Only for eyes which required filtration  
surgery) 
The complications caused during YAG PI procedure was 
predominantly mild Uveitis/iritis with mild rise in IOP in the entire sample 
group with similar finding in 23 eyes of the total 30 eyes which required 
filtration  surgery after LPI. In a similar study by Ching-HsiHsiao et al in 
Asian eyes, Mild iritis with mild rise in IOP was seen in 54 patients (23.5%) 
and Mild iris bleeding was seen in 28 eyes (12.2%). But no significant long 
term effects leading to glaucoma progression due to the LPI complications 
could be observed. 
VISUAL ACUITY:  
The visual acuity of all patients who had undergone YAG PI with or 
without trabeculectomy surgery were converted into LogMAR units for 
comparision in our study. The median presenting visual acuity was 0.18 at 
time of presentation, which worsened to 0.30 after an 6 months which 
deteriorated in 12 months which was statistically significant. (P value < 
0.001). 
We also observed that among the patients under study. 50 eyes of 80 
patients, who had undergone YAG PI and did not require any filtration 
surgery had no significant deterioration of visual acuity in the follow up 
 
 
period. While, the. 30 eyes of 80 who had undergone YAG PI and also 
required trabeculectomy had almost significant deterioration of visual acuity 
in the follow up period (0.39 to 0.48 with P value of 0.008).  This is 
comparable to the study by Ching-His Hsiao et al in which there was no 
significantdeterioration of visual acuity in the 6 month follow up period in 
PACG patients who had undergone only YAG PI in about 92.3% 
INTRA OCULAR PRESSURE 
The mean pre-operative IOP was in the range of 21 – 64 mmHg and 
mean (SD) was 30.21(11.68) in our study group. It was comparable to the 
study by Ching-Hsi Hsiao et al, which showed  a mean IOP of 25.4 ± 7.1, in 
the study by Alsagoff Z et al, which showed  a mean IOP of  40 ± 15, and 
the study by Rosman M et al, which showed  a mean IOP of 31 ±12.5. In 
our study we noted that, the Mean Preop YAG PI,  IOP was 30.21(11.68) 
which declined to a mean IOP of 17.74 in last follow up after undergoing 
YAG PI, irrespective of patients who required additional medications or 
additional filtration surgery which was statistically significant ( p value 
<0.001). 
We also observed that among the patients under study. 50 eyes of 80 
who had undergone YAG PI and did not require any filtration surgery had 
significant decreasein IOP in the follow up period (25.88 to 20.46 with p 
 
 
value  <0.001 which was statistically significant).While, the. 30 eyes of 80 
who had undergone YAG PI and also required trabeculectomy  also  had 
relatively higher pre YAG PI IOP and  poor IOP control (37.43 to 28.63) 
and hence underwent trabeculectomy which showed a significant decrease 
in IOP in the follow up period (27.53 to  17.00  with a  p value  <0.001 
which was statistically significant). This is comparable to study by Ching-
His Hsiao et al in which there was significant decrease in IOP in the follow 
up period in patients who had undergone YAG PI alone in the follow up 
period (25.4 ± 7.1 to  14.5 ± 4with p value  <0.001 which was statistically 
significant )  and there was much significant decrease in IOP in the follow 
up period in patients who had undergone YAG PI along with filtration 
surgery within the follow up period (43.3 ± 19.8 to  12.4 ± 3.3 with p value  
<0.001 which was statistically significant )   
GONIOSCOPY 
Among Gonioscopic findings at time of presentation and 3 months 
post op in 80 eyes, 35 eyes(43.7)% had >270 degree of angle closure 
without Peripheral anterior synechiae, around 45 eyes(56.3)% had >270 
degree of angle closure with Peripheral anterior synechiae. 
On follow up visit in 3 months, of the 80 eyes which had undergone 
YAG PI eyes (Of which 10 patients have already undergone 
 
 
trabeculectomy)  ,  35eyes (43.7%) had narrow angles with PAS, 35 
eyes(43.7%) had angles narrow angles without PAS,open on indentation, 
and 10 eyes(12.5%) had narrow angles with Patent ostium. 
It was also noticed that, of the 30 eyes which required additional 
trabeculectomy post YAG PI, almost 29 eyes (96.7%) had preop had >270 
degree of angle closure with Peripheral anterior synechiae and only 1 patient 
had >270 degree of angle closure without Peripheral anterior synechiae.  
This is comparable to the study by byChing-His Hsiao et al in which 
on analysing the gonioscopic findings of 10 eyes which underwent 
trabeculectomy or the triple procedure to control IOP within 6 months after 
YAG PI,  8 eyes  actually had peripheral anterior synechiae (PAS) of more 
than 270°. Hence, presence of synechial angle closure seems to play a major 
role in failure of YAG PI. 
VISUAL FIELDS 
On evaluation of Visual field defects, at initial presentation, we found 
that 34 patients (42.5%)  had Superiorarcuatescotoma, 32 patients (40%) 
was having double arcuatescotoma and 10 patients (12.5%) had advanced or 
end stage field defects. And at 6 months follow up period, it was noticed 
that, the superior and Inferior arcuatescotoma has progressed to double 
 
 
arcuatescotoma in 2 patients making it 34 (42.5%), while the patients with 
advanced or end stage field defects did not show any change. 
CUP TO DISC RATIO (CDR) 
Cup disc ratio is directly correlated to the severity of glaucomatous 
damage. Higher the cup disc ratio, poorer the prognosis of long term IOP 
control. In our study, The cup disc ratio at initial presentation had a mean 
value of 0.73 (0.13) which did not show any significant change in the 3 
month follow up, while it worsened to 0.74 in the 6 month follow up period 
which was significant. 
This was comparable to the study by Rosman et al in which the study 
population had a mean presenting CDR of 0.7 ± 0.2 and Alsagoff et al 
which had a had a mean presenting CDR of 0.6 ± 0.2. 
ANTI-GLAUCOMA MEDICATION: 
In our study, we observed that, the Number of antiglaucoma 
medications prescribed after YAG PI had a mean of 1.23 at 2 weeks follow 
up period, which increased to 1.49 at 3 month follow up , but it reduced to 
1.20 and 1.15 at the 6 month and 1 year follow up period respectively. 
We also observed that among the patients under study,  almost all of  
them are newly diagnosed with PACG at presentation and none of the were 
already using any antiglaucoma medications. Also,  all the patients who 
 
 
underwent YAG PI,  eventually required antiglaucoma medication for IOP 
control. In the 50 eyes of 80 who had undergone YAG PI and did not 
undergo any filtration surgery  required antiglaucoma medications of mean 
value 1.06.. While, the. 30 eyes of 80 who had undergone YAG PI and also 
required trabeculectomy  required antiglaucoma medications of mean value 
1.70 before trabeculectomy, which decreased to 0.71 after trabeculectomy in 
the follow up period with a  p value  <0.001 which was statistically 
significant). 
This is similar to the study by Rosman et al, in which all 80 eyes 
(100%) in the study group which underwent YAG PI required additional 
antiglaucoma medications and IOP control was achieved with medications 
alone in 33 eyes of 80 (41.3%) and in the study by Alsagoff et al, in which 
78 eyes (94%) in the study group which underwent YAG PI, required 
additional antiglaucoma medications and IOP control was achieved with 
medications alone in 34 eyes of 78 (41.0%). Also, in the study by Salmon J 
et al, in which the study group which underwent YAG PI, and required 
additional antiglaucoma medications, IOP control was achieved with 
medications alone in 40 eyes of 78 (51.3%). And in the study by Ching-Hsi 
Hsiao et al, in almost 95.3% of the eyes which underwent YAG PI,the 
number of medications remained  the same or it decreased in number, and 
only 4.7% of eyes required more number of medications to control IOP. 
 
 
And at last follow up, 52.2% of eyes did not require any medications which 
included eyes which had undergone filtration surgery.  
NEED FOR FILTRATION SURGERY  
Of the 80 eyes, which had undergone YAG PI, around 30 eyes 
(37.5%) eventually required Trabeculectomy surgery and almost 50 eyes did 
not require any filtration procedure for IOP control which was comparable 
to the studies by Rosman M et al, 25 of 80 eyes (31.3%), the study by 
Alsagoff Z at al, 44 of 83 eyes (53%), and the study by Salmon et al, 23 of 
72(29.5%) eyes,which eventually required filltration surgery.  
While according to the study by Winifred P Nolan et al, 13 eyes of 
164 eyes (7.9%) and  study by Ching-HsiHsiao et al, 16 of 83 eyes (19.2%), 
Our study shows higher number of eyes which eventually required filltration 
surgery. 
TIMING OF TRABECULECTOMY POST LASER PERIPHERAL 
IRIDECTOMY 
Of the 30 eyes which required trabeculectomy post YAG PI, 23 
eyes(76.7%) required trabeculectomy  within a duration of 1-6 months post 
LPI, 5 eyes (16.7%) within 1 month and 2 eyes(6.6%) after 6 months-1 year. 
While comparing the  mean time to trabeculectomy after LPI, according to 
study by Salmon et al it was 9.9 months (1.5 to 24 months),in the 
 
 
comparative study by Alsagoff Z, it was 7.3,18.4 months, in the study by 
Ching-HsiHsiao et al, it was 6 to 24 months. This shows that, most of the 
patients in our study group required surgery relatively earlier in comparison 
to other study groups. 
Correlation between Timing of trabeculectomy post Laser Peripheral 
Iridectomy and preoperative factors like IOP, Goniocopy and Cup disc ratio 
was analysed. We could observe that, in the 5 patients who underwent 
trabeculectomy within a month duration, on comparison with the eyes which 
underwent trabeculectomyat a later period, had a relatively higher mean 
CDR of 0.82 ± 0.08, Higher mean IOP of 34.40 ± 12.34 mm Hg, and 100% 
of them had Preopgonioscopy showing >270 degree angle closure with 
PAS. Also, we noticed that almost 29 of 30 eyes  (96.7%) which  eventually 
underwent trabeculectomy post PI had Preopgonioscopy showing >270 
degree angle closure with PAS. 
MEDICAL & SURGICAL OUTCOME 
To summarize, we found that, only 11 eyes of 30 (36.6%) who 
underwent trabeculectomy after YAG PI did not require any additional 
antiglaucoma medications and had no long term IOP rise in the follow up 
period. and additional antiglaucoma medications after YAG PI was needed 
in all 50 patients (100%) and additional antiglaucoma medications after 
Trabeculectomy was needed in 19 of 30 patients (63.4%) 
 
 
 According to study by Alsagoff et al, Only 5 eyes of 80 (6%) with 
LPI alone had  no long term IOP rise in the follow up period, remaining 78 
eyes (94%) required additional antiglaucoma medications. And further 44 
eyes (56.4%) of this who underwent trabeculectomy did not require 
antiglaucoma medications in long term follow up. And According to a 
similar study by Rosman et al, all 80 eyes (100%) which underwent YAG PI 
required additional antiglaucoma medications. And further 25 eyes (31.3%) 
of this who underwent trabeculectomy did not require any antiglaucoma 
medications and 22 eyes (27.5%) which underwent Laser 
trabeculoplasty/Iridoplasty needed antiglaucoma medications. 
Also, based on our primary outcome, i.e Intra ocular pressure, A 
success is defined as ability to lower the IOP (IOP<=21) and failure is 
inability to lower IOP (IOP>21).  And Along with medications, YAG PI 
alone was  found to be successful in 39 of 50 patients (78%) and additional 
Trabeculectomy after YAG PI  was  found to be successful in 29 of 30 
patients (96.7%). In the study by Winifred P Nolan et al, , A success is 
defined as ability to lower the IOP (IOP<21) and failure is inability to lower 
IOP (IOP>19). In a total of 27 patients, who had preop YAG PI IOP >19, 
YAG PI alone was  found to be successful in 15 of 27 patients (55.5%) and 
Additional medical management was required in 8 of 27 patients (96.7%) 
 
 
and additional Trabeculectomy after YAG PI  was  found to be successful in 
4 of 27 patients (96.7%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
In our prospective observational case series study, done to study the 
long-term clinical course, outcome & efficacy of  treatment in primary angle 
closure glaucoma affected patients who undergone Nd-YAG Laser 
iridotomy with primary outcome being Intraocular pressure (IOP), and 
secondary outcome being Gonioscopy, Visual field,  we could reach at the 
following conclusions: 
· YAG PI is recommended as the primary treatment in the management 
of PACG and PAC.The complications caused during YAG PI 
procedure was predominantly mild Uveitis/iritis. But no significant 
long term effects leading to glaucoma progression due to the LPI 
complications could be observed. 
· Of all the eyes which underwent YAG PI, 37.5% eventually required 
Trabeculectomy surgery for IOP control 
· Almost 76.7% required trabeculectomy within a duration of 1-6 
months post YAG PI. 
· Almost 97% of the patient who underwent trabeculecomy after failure 
of YAG PI had >270 degree of angle closure with Peripheral anterior 
synechiae in preopgonioscopy findings. 
 
 
· IOP control was significant in eyes which required only YAG PI and 
Eyes which required additional trabeculectomy had a higher 
preoperative IOP value which reduced significantly after the 
procedure 
· It was observed that Patient who had undergone YAG PI alone and 
did not require any filtration surgery had no significant deterioration 
of visual acuity in the follow up period. While, the. eyes that 
underwent YAG PI and also required trabeculectomy had almost 
significant deterioration of visual acuity in the follow up period. This 
could be attributed to the advanced glaucomatous changes and 
relatively higher IOP with presence of PAS in the eyes that required 
trabeculectomy and also trabeculectomy related astigmatism. 
· Most of the patients in our study group had superior arcuate scotoma  
at time of presentation which further worsened to double arcuate 
scotoma at the last follow up period, while the patients with advanced 
or end stage field defects did not show any change. 
· In our study group almost all patients required antiglaucoma 
medications after YAG PI. In general, in all patients there was a 
decline in the mean number of antiglaucoma medications needed in 
the last follow up visit. Also, In patients who had undergone 
 
 
trabeculectomy, The mean number of medications after the procedure 
had decreased significantly.  
· Additional antiglaucoma medications were needed in 86%of the 
patients who had undergone YAG PI alone and 64.3% of the patients 
who had undergone trabeculectomy after failed YAG PI. 
· Hence, to summarize Nd-YAG Laser iridotomy with antiglaucoma 
medications is found to be effective in controlling the glaucoma 
progression in cases of PACG with > or = 270 angle closure without 
PAS, relatively lesser IOP and absence of advanced glaucomatous 
cupping or field defects at initial presentation and Trabeculectomy 
was found to be very much successful in controlling the IOP and 
retard the progression of PACG in failed cases of YAG PI with or 
without medications, especially in >270 degree synechial angle 
closure cases, even though a deterioration in visual acuity was noticed 
in last follow up which could be attributed due to the natural course 
of the disease.  
 
 
 
 
LIMITATIONS 
v Small sample size. 
v Short duration of study 
v Late complications due to Trabeculectomy surgery could not be 
evaluated due to shorter follow up period. 
RECOMMENDATIONS 
v Larger study population and longer follow up duration has to been 
included. 
 
 
 
 
Ultrasonic or laser based chamber depth measurement 
 
 
 
 
 
 
 
FIG1: PARACENTRAL SCOTOMA 
 
FIG 2: ARCUATE SCOTOMA (SUPERIOR) 
 
 
 
FIG 3: NASAL STEP 
 
 
FIG 4: ALTITUDINAL WITH END STAGE,COMPLETE  
FIELD LOSS 
 
 
 
 
 
 
 
FORNIX BASED CONJUCTIVAL FLAP 
 
MITOMYCIN C  PLACED IN SUB CONJUCTIVAL 
SPACE 
 
 
 
 
 
PARTIAL THICKNESS SCLERA FLAP DISSECTION 
 
 
KELLY  DESCEMET’S HAS BEEN USED TO CREATE A 
SCLEROSTOMY 
 
 
SUPERIOR RELEASABLE SUTURE 
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STUDY PROFORMA 
 
NAME:                                                          M.R.NO.: 
AGE:                                                              PROFORMA NO: 
SEX:      M               F                                            DATE: 
ADDRESS:      OCCUPATION: 
 
CONTACT NO: 
CHIEF COMPLAINTS: 
STUDY EYE: RE -1 
   LE -2 
                         BE - 3  
Complaints & Duration: 
H/o. Any previous treatment/ocular surgeries: 
H/o.YAG PI done:      Yes               No               
If Yes, Date & details:                    
 
 
 
 
Ocular Medications:  
No. of drugs: 
Frequency & Details: 
Any systemic Illness                         Yes    No 
  
  
       If yes 
 
A. Nature of Illness    
      
1. Hypertension 
 
2. Diabetic mellitus 
 
3. Asthma 
 
4. IHD 
 
5. Cerebrovascular Accident 
 
6. Hypercholesterolemia 
7. Others (Specify)   
 __________________________ 
FAMILY HISTORY: 
 
 
: 
 
TREATMENT HISTORY: 
: 
EXAMINATION: 
Visual acuity: 
Without glasses: 
With glasses: 
ANTERIOR SEGMENT EVALUATION: 
With slit lamp bio microscopy: 
                                                     (RE)                                                     (LE) 
Ø LIDS 
Ø CONJUNCTIVA 
Ø CORNEA 
Ø ANTERIOR CHAMBER 
o Depth 
o Grade 
o Status  
Ø PUPILS 
Ø IRIS 
 
 
o PI status 
Ø LENS 
 
 
Ø FUNDUS 
o Cup-disc ratio 
o RNFL 
o Macula 
o Background retina 
 
INVESTIGATIONS: 
REFRACTION AND CORRECTION: 
Retinoscopy:   
(RE)                                                         (LE) 
 
Correction: 
 
 Sphere Cylinder Axis V/A 
RE     
 
 
LE     
 
 
 
INTRAOCULAR PRESSURE: 
                                                           (RE)                                                   
(LE) 
NCT          : _____  mmHg   _____  mmHg 
APPLANATION TONOMETER 
    (Corrected)                                   :_____  mmHg   _____  mmHg 
 
Ø GONIOSCOPY: 
o GRADE: 
o PIGMENTATION: 
o Others: 
Ø HFA 
DIAGNOSIS: 
RE: 
LE: 
 
 
 
 
MANAGEMENT 
LASER PROFORMA: 
STUDY EYE: RE -1 
                         LE -2 
                         BE - 3  
PRE-LASER MEDICATIONS: Pilocarpine 2% 
IMMEDIATE PRELASER IOP: 
LASER SETTINGS: 
Ø ENERGY: 
Ø PULSE: 
Ø NO OF SHOTS: 
Ø POSITION: 
 POST OPERATIVE OCULAR DATA 
· IOP during the follow-up period: 
· Antiglaucoma treatment required (if any), Number of medications,  
including the time of commencing treatment and the type of 
treatment; 
 
 
 
 
 
 
· Surgery required (if any), including the indication, timing, and type of 
surgery; 
 
SURGICAL MANAGEMENT: 
Date: 
Type of surgery: Trabeculectomy with MMC/ Glaucoma triple procedure. 
Operating surgeon: 
Anaesthesia 
 
  
 
 
ABBREVIATIONS 
IOP  - Intra Ocular Pressure 
CCT  - Central Corneal Thickness 
ACD  - Anterior Chamber Depth 
PAS  - Peripheral Anterior Synechiae 
PAC  - Primary Angle Closure 
PACS - Primary Angle Closure Suspect 
PACG - Primary Angle Closure Glaucoma 
CDR  - Cup to Disc Ratio 
Nd-YAG - Neodymium- Yttrium Aluminium Garnet 
LPI  - Laser Peripheral Iridectomy. 
 
 
 
 
 
 
 
Informed Consent form to participate in a clinical trial 
Study Title: LONG-TERM CLINICAL COURSE, OUTCOME & 
EFFICACY OF  TREATMENT  IN PRIMARY ANGLE CLOSURE 
GLAUCOMAIN A TERTIARY EYE CARE HOSPITAL IN SOUTH INDIA. 
 
Protocol Number: 
  
Subject’s Name_______________Subject’s Initials: _______________  
  
Subject ID No: _________________  
 
Date of Birth / Age: _________________  
  
    Please put initial in the 
box (Subject) 
(i) I confirm that I have understood the 
information about the study, procedures and 
treatments for the above study and have had 
the opportunity to ask questions and I 
received satisfactory answers to all of my 
questions.  I have been given a copy of the 
informed consent form to take home 
  
[         ] 
 
 
(ii) I understand that my participation in the 
study is voluntary and that I am free to 
withdraw at any time, without giving any 
reason, without my medical care or legal 
rights being affected. However, this is may  
not be possible for certain surgical 
procedures  
[         ] 
(iii
) 
I understand that the Investigator of the 
study to access my health records for the 
research purpose. However, I understand 
that my identity will not be revealed in any 
information released to third parties or 
published. 
[         ] 
(iv) I agree not to restrict the use of any data or 
results that arise from this study provided 
such a use is only for scientific purpose(s) 
[        ] 
  
(v) I agree to take part in the above study. 
  
          [         ] 
    
Signature (or Thumb impression) of the Subject: 
_____________________________  
  
 Date: _____/_____/______ 
  
Subject’s Name:  
_________________________________________________ 
  
 
 
Signature (or Thumb impression) of Legally Acceptable Representative 
(LAR):___________________________________________             
  Date: ____________  
 
 
Signature of the Investigator: ___________________________ 
Date: _____/_____/______ 
  
Investigator’s Name: 
_____________________________________________ 
  
 
Signature of the Witness 
________________________________________               
 Date:  
_____/_____/_______  
  
Name of the Witness:  
_____________________________________________ 
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PI
RE  6/9 PACG 1 0.7 1 28 7/4/2013 2 0 18 23 17 17 17 1 2 2 2 2 1 0.7 0.75  6/9  6/9  6/12  6/12  6/12 1
LE  6/9 PACG 2 0.8 2 34 7/4/2013 2 0 25 25 17 19 19 1 2 1 1 1 2 0.8 0.8  6/9  6/9  6/12  6/24  6/24 2 12/11/2013 5 months
RE  6/24 PACG 2 0.9 3 36 7/10/2013 2 2 51 20 13 15 15 1 2 2 1 1 3 0.9 0.9  6/24  6/24  6/36  6/36  6/36 3 8/16/2013 1
LE  6/24 PACG 2 0.9 3 32 7/10/2013 2 2 34 17 17 16 16 1 2 2 1 1 3 0.9 0.9  6/24  6/24  6/24  6/36  6/36 3 9/19/2013 2
RE  6/12 PACG 2 0.7 2 25 9/18/2013 3 2 19 14 13 14 14 1 2 2 2 2 2 0.6 0.6  6/12  6/12  6/12  6/24  6/24 2
LE  6/18 PACG 2 0.9 3 56 9/18/2013 3 2 23 16 17 16 16 1 1 1 1 1 3 0.9 0.9  6/18  6/18  6/18  6/36  6/36 3 10/25/2013 1
RE  6/9 PACG 1 0.7 2 22 7/4/2013 2 2 18 23 17 17 17 1 3 2 2 2 1 0.7 0.7  6/9  6/9  6/9  6/9  6/9 2
LE  6/9 PACG 2 0.8 3 34 7/4/2013 2 2 25 25 17 19 19 1 3 1 1 1 2 0.8 0.85  6/9  6/9  6/12  6/12  6/12 3 12/11/2013 5
RE  6/18 PACG 2 0.9 3 56 8/4/2013 2 2 43 38 17 10 10 3 3 1 1 1 2 0.9 0.9  6/18  6/18  6/18  6/24  6/24 3 11/13/2013 3
LE  6/9 PACG 1 0.7 2 26 8/4/2013 2 0 30 19 20 21 21 2 2 2 2 2 2 0.7 0.7  6/9  6/9  6/9  6/9  6/9 2
RE  6/9 PACG 1 0.65 2 21 8/30/2013 3 2 19 18 16 17 18 1 2 2 2 2 1 0.7 0.7  6/9  6/9  6/9  6/9  6/9 2
LE  6/18 PACG 2 0.95 4 64 8/30/2013 3 2 24 20 16 19 19 1 1 0 0 0 2 0.95 0.95  6/18  6/18  6/18  6/24  6/24 4 12/10/2013 4
RE  6/6 PACG 1 0.6 2 22 9/4/2013 3 2 19 17 16 15 15 2 1 1 1 1 1 0.6 0.6  6/6  6/9  6/9  6/12  6/12 2
LE  6/36 PACG- 2 0.7 2 42 9/4/2013 3 2 24 25 17 14 14 1 2 0 0 0 2 0.7 0.75  6/36  6/36  6/36  6/36  6/36 2 1/5/2014 4
RE  6/9 PACG 1 0.65 2 21 9/10/2013 2 0 22 19 17 16 15 2 1 1 1 1 1 0.65 0.7  6/9  6/9  6/9  6/12  6/12 2
LE  6/9 PACG 2 0.9 3 34 9/10/2013 2 0 25 16 19 15 15 2 2 1 1 1 2 0.9 0.9  6/9  6/9  6/9  6/12  6/12 3 12/19/2013 3
RE  6/24 PACG- 2 0.65 2 50 8/25/2013 2 0 45 26 15 14 14 2 2 0 0 0 1 0.7 0.8  6/24  6/24  6/24  6/36  6/36 3 12/16/2013 4
LE  6/6 PACG 1 0.6 2 22 8/25/2013 2 0 19 18 17 19 19 2 1 1 2 2 1 0.6 0.65  6/6  6/9  6/9  6/9  6/9 2
RE PL PACG- 2 GOA 4 52 9/30/2013 3 2 38 42 40 21 21 2 2 3 3 3 2 GOA GOA PL PL PL PL PL 4
LE  6/9 PACG 2 0.85 3 36 9/30/2013 3 2 30 32 20 19 19 2 3 0 0 0 2 0.85 0.85  6/9  6/12  6/24  6/24  6/24 3 12/12/2013 3
RE  6/6 PACG- 2 0.9 3 28 9/6/2013 2 0 22 24 20 19 19 2 2 0 0 0 2 0.9 0.9  6/6  6/6  6/6  6/12  6/12 3 12/15/2013 3
LE PL- PACG- 2 GOA 4 48 9/6/2013 2 0 30 25 31 28 28 3 3 3 3 3 2 GOA GOA PL- PL- PL- PL- PL- 4
RE  6/24 PACG- 2 0.85 3 56 8/16/2013 3 2 25 24 19 16 16 1 1 1 1 1 2 0.85 0.85  6/24  6/24  6/24  6/36  6/36 3 11/30/2013 3
LE  6/24 PACG- 2 0.8 3 38 8/16/2013 3 2 20 20 23 17 17 1 1 1 1 1 2 0.8 0.8  6/24  6/24  6/36  6/36  6/36 3 3/18/2014 7
RE  6/6p PACG- 2 0.8 3 50 8/15/2013 3 0 36 19 16 17 17 1 0 1 1 1 3 0.8 0.8  6/6p  6/6p  6/9  6/12  6/12 3 10/6/2013 2
LE PL PACG 2 GOA 4 54 8/15/2013 3 0 32 38 44 45 45 1 1 1 1 1 2 GOA GOA PL PL PL PL PL 4
RE  6/9 PACG- 1 0.65 3 22 8/8/2013 2 0 21 23 17 16 16 2 2 1 1 1 1 0.65 0.65  6/9  6/9  6/9  6/12  6/12 3
LE  6/12 PACG- 2 0.85 4 32 8/8/2013 2 0 28 25 24 15 15 2 2 1 0 0 2 0.85 0.85  6/12  6/12  6/12  6/24  6/24 4 2/1/2014 6
RE  6/9 PACG- 2 0.7 3 29 8/6/2013 2 2 26 19 16 18 18 2 1 1 1 1 3 0.7 0.8  6/9  6/9  6/12  6/12  6/12 3 9/13/2013 1
LE  6/9 PACG- 2 0.85 3 30 8/6/2013 2 2 27 24 26 19 19 2 2 1 1 1 2 0.85 0.85  6/9  6/9  6/12  6/12  6/12 3 12/9/2013 4
RE HM PACG- 2 0.9 3 30 9/7/2013 2 0 18 23 17 17 17 2 2 2 2 2 1 0.9 GOA HM HM HM HM HM 3
LE  6/12 PACG- 2 0.8 3 22 9/7/2013 3 2 25 25 17 19 19 2 2 1 1 1 2 0.8 0.8  6/12  6/12  6/12p  6/24  6/24 3 12/11/2013 3
RE  6/6 PACG- 2 0.9 4 36 9/25/2013 3 2 34 24 19 17 17 1 2 1 1 1 2 0.9 0.9  6/6  6/6  6/9  6/12  6/12 4 2/27/2014 5
LE  6/6p PACG- 1 0.7 3 29 9/25/2013 2 2 18 22 18 16 16 1 2 1 1 1 2 0.7 0.7  6/6p  6/6p  6/6p  6/6p  6/6p 3
M RE  6/9 PACG- 1 0.7 3 23 9/23/2013 2 0 22 19 18 16 16 1 1 1 1 1 2 0.7 0.7  6/9  6/9  6/9  6/12  6/12 3
LE  6/9 PACG- 2 0.8 3 34 9/23/2013 3 0 27 21 20 19 19 2 2 1 1 1 3 0.8 0.85  6/9  6/9  6/9  6/12  6/12 3 12/11/2013 3
RE  6/18 PACG,imc 2 0.7 3 28 8/18/2013 2 2 24 23 17 17 17 1 1 0 0 0 3 0.7 0.8  6/18  6/18  6/18  6/24  6/24 3 11/6/2013 3
LE  6/12 PACG,imc 2 0.6 3 24 8/18/2013 2 2 21 21 22 15 15 1 1 1 0 0 2 0.6 0.7  6/12  6/12  6/12  6/18  6/18 3 2/22/2014 6
RE  6/6 PACG- 1 0.6 3 26 10/19/2013 2 2 18 21 19 17 17 1 2 2 2 2 1 0.6 0.6  6/6  6/6  6/6  6/6  6/6 3
LE  6/9 PACG- 2 0.8 3 30 10/19/2013 3 2 23 17 19 18 18 1 1 0 0 0 3 0.8 0.85  6/9  6/9  6/9  6/9  6/9 3 12/11/2013 2
RE  6/18 PACG- 1 0.7 3 24 7/4/2013 2 2 23 22 17 17 17 1 1 2 2 2 1 0.7 0.7  6/18  6/18  6/18  6/18  6/18 3
LE  6/18 PACG- 2 0.85 3 22 7/4/2013 2 2 25 25 17 19 19 2 2 1 1 1 2 0.85 0.85  6/18  6/18  6/18  6/24  6/24 3 12/11/2013 5
RE  6/12 PACG- 2 0.6 3 42 8/25/2013 2 2 24 19 20 19 19 2 2 2 2 2 2 0.6 0.65  6/12  6/12  6/12  6/18  6/18 3
LE  6/9 PACG- 2 0.8 4 49 8/25/2013 2 2 28 16 17 18 18 2 1 1 1 1 3 0.8 0.85  6/9  6/9  6/9  6/12  6/12 4 10/14/2013 2
RE  2/60 PACG- 2 0.8 3 62 8/2/2013 3 2 44 16 17 17 17 2 1 0 0 0 3 0.8 0.8  2/60  2/60  1/60  1/60  1/60 3 9/14/2013 1
LE  6/36 PACG- 1 0.6 2 24 8/2/2013 3 2 22 28 24 19 19 1 2 2 1 1 2 0.6 0.75  6/36  6/36  6/36  6/60  6/60 2 8/19/2014 12
3 Paranjothi a 61 M
4 Selvi P 65 F
1 Maria Ayesha 65 F
2 Bhagavan Das 60 M
7 Pommu V 40 F
8 Ravi Sankar M 44 M
FAdhi Narayanamma 505
6 Krishnan R 45 M
11 Muthusamy 64 M
12 Selvi P 48 F
9 Chellayee V 44 F
10 Jeyabal 63 M
15 Mohammed Thajudeen 58 M
16 Sujatha 54 F
13 Annapooranam P 52 F
14 Ummul Sahitha 65 F
19 Dharmalingam 62 M
20 Radhakrishnan 55 M
17 Jayapandian 74 M
18 Premkumar 55
23 Saraswathi 63 F
21 Balasubramaniam 60 M
22 Murugan 64 M
Co
m
pl
ic
at
io
ns
IOP Post op V/ANo. of Medications POST OP CDR
MASTER CHART
Di
ag
no
sis
Go
ni
o
cd
r
Pr
eo
p 
IO
P
YA
G 
PI
 D
AT
E
LP
I 
Vi
su
al
 fi
el
ds
N
am
e
Ge
nd
er
Ag
e
Ey
e
V/
A
S.
N
o
RE  6/6 p PACG-PCIOL 1 0.65 2 24 9/21/2013 2 2 22 21 20 19 19 1 2 2 2 2 1 0.65 0.65  6/6 p  6/6 p  6/6 p  6/9  6/9 2
LE  6/24 PACG- 2 0.8 3 27 9/21/2013 2 2 28 17 15 16 16 2 0 0 0 0 3 0.8 0.85  6/24  6/24  6/24  6/36  6/36 3 9/28/2013 1
RE  6/6P PACG- 2 0.75 2 22 10/12/2013 2 2 20 19 17 16 16 1 1 2 2 2 2 0.75 0.75  6/6P  6/6P  6/6P  6/9  6/9 2
LE  6/18 PACG- 2 0.8 3 28 10/12/2013 2 2 25 17 18 19 19 1 1 1 1 1 3 0.8 0.8  6/18  6/18  6/18  6/24  6/24 3 12/11/2013 2
RE  6/9 PACG 1 0.65 1 23 8/14/2013 2 0 22 21 17 16 16 1 2 2 2 2 1 0.65 0.65  6/9  6/9  6/9  6/9  6/9 1 NIL
LE  6/9 PACG 1 0.75 2 22 8/14/2013 2 0 20 19 18 17 17 1 2 2 2 2 1 0.75 0.75  6/9  6/9  6/9  6/9  6/9 2 NIL
RE  6/18 PACG 1 0.8 2 22 9/19/2013 2 2 19 12 18 17 17 1 1 1 1 1 1 0.8 0.8  6/18  6/18  6/18  6/18  6/18 2 NIL
LE  6/24 PACG 1 0.65 2 23 9/19/2013 2 2 18 19 17 15 15 2 2 1 1 1 1 0.65 0.65  6/24  6/24  6/24  6/24  6/24 2 NIL
RE  6/6 PACG- 1 0.6 1 22 6/30/2013 3 0 18 19 16 14 16 1 1 1 1 1 1 0.6 0.65  6/9  6/9  6/9  6/9  6/9 1 NIL
LE  6/18P PACG- 2 0.8 3 26 6/30/2013 3 0 20 16 19 18 18 2 2 2 2 2 1 0.8 0.8  6/18P  6/18P  6/18P  6/18P  6/18P 3 NIL
RE PL PACG- 1 GOA 4 25 8/17/2013 2 2 21 20 19 20 20 1 1 1 2 2 2 GOA GOA PL PL PL PL PL 4
LE  6/60 PACG 1 0.7 1 22 8/17/2013 2 2 19 18 17 19 19 1 1 1 1 1 1 0.7 0.7  6/60  6/60  6/60  6/9  6/9 1 PHACO WITH IOL
RE  6/12 PACG- 1 0.6 1 21 8/30/2013 1 2 19 18 17 16 16 1 1 1 1 1 1 0.6 0.65  6/12  6/12  6/12  6/24  6/24 1 NIL
LE  6/9 PACG 2 0.65 1 24 8/30/2013 1 2 20 20 19 18 18 1 1 1 2 2 1 0.65 0.7  6/9  6/9  6/9  6/12  6/12 1 NIL
RE  6/9 PACG- 2 0.8 2 27 8/21/2013 1 2 20 23 19 18 18 1 2 2 2 2 1 0.8 0.8  6/9  6/9  6/9  6/12  6/12 2 NIL
LE  6/6P PACG 1 0.75 2 21 8/21/2013 1 2 17 18 16 15 15 1 1 1 2 2 1 0.75 0.75  6/6P  6/6P  6/6P  6/9  6/9 2 NIL
RE PL PACG- 2 GOA 4 56 8/9/2013 2 0 30 34 28 30 30 2 2 2 2 2 2 GOA GOA PL PL PL PL PL 4
LE  5/60 PACG 1 0.65 2 24 8/9/2013 1 0 19 18 19 16 16 1 1 1 1 1 1 0.65 0.65  5/60  5/60  5/60  6/12  6/12 2 PHACO WITH IOL
RE  6/6 PACG- 2 0.7 2 23 8/29/2013 2 2 20 19 19 18 18 2 2 2 1 0.7 0.7  6/6  6/6  6/6  6/9  6/9 2 NIL
LE  6/9 PACG 1 0.65 2 24 8/29/2013 2 2 19 18 19 17 17 1 1 1 1 1 1 0.65 0.65  6/9  6/9  6/9  6/12  6/12 2 NIL
RE  6/6 PACG- 1 0.7 2 24 9/18/2013 2 2 20 19 18 17 17 1 1 1 1 1 1 0.7 0.7  6/6  6/6  6/9  6/9  6/9 2 NIL
LE  6/9 PACG 1 0.75 2 23 9/18/2013 2 2 20 18 16 17 17 1 1 1 1 1 1 0.75 0.75  6/9  6/9  6/9  6/12  6/12 2 NIL
RE  6/12 PACG- 1 0.65 2 24 9/3/2013 2 0 19 19 18 19 19 1 1 1 1 1 1 0.65 0.65  6/12  6/12  6/12  6/12  6/12 2
LE  6/9 PACG 1 0.6 2 22 9/3/2013 2 0 19 16 17 18 18 1 1 1 1 1 1 0.6 0.65  6/9  6/9  6/9  6/9  6/9 2 NIL
RE  6/9 PACG 2 0.75 2 20 9/17/2013 3 0 19 18 20 19 19 1 1 1 1 1 1 0.75 0.75  6/9  6/9  6/9  6/12  6/12 2 NIL
LE  6/12 PACG 2 0.75 2 22 9/17/2013 3 0 18 16 16 18 18 1 1 1 1 1 1 0.75 0.75  6/12  6/12  6/12  6/18  6/18 2 NIL
RE  6/9 PACG 1 0.8 2 24 9/24/2013 2 2 17 21 20 19 19 1 2 2 2 2 1 0.8 0.8  6/9  6/9  6/9  6/12  6/12 2 NIL
LE  6/6p PACG 1 0.8 2 22 9/24/2013 2 2 18 22 19 19 19 1 2 2 2 2 1 0.8 0.8  6/6p  6/6p  6/6p  6/9  6/9 2 NIL
RE  1/60 PACG/ IMC 1 0.8 3 24 7/1/2013 2 2 15 16 15 17 17 1 1 1 1 1 1 0.8 0.8  1/60  1/60  1/60  6/18  6/18 3 PHACO WITH IOL
LE  HM PACG 2 0.9 GOA 4 28 7/1/2013 2 2 21 20 18 19 19 1 2 2 2 2 2 0.9 GOA 0.9 GOA  HM  HM  HM  HM  HM 4
RE  6/12 PACG 2 0.85 3 26 9/30/2013 2 0 22 19 18 15 15 1 2 2 2 2 2 0.85 0.85  6/12  6/12  6/12  6/18  6/18 3 NIL
LE  6/9 PACG 1 0.7 2 21 9/30/2013 3 0 21 18 17 18 18 1 2 2 2 2 2 0.7 0.8  6/9  6/9  6/9  6/12  6/12 2 NIL
RE  6/6 PACG 1 0.85 2 24 9/30/2013 2 0 21 19 18 17 17 1 2 2 2 2 1 0.85 0.85  6/12  6/12  6/18  6/18  6/18 2 NIL
LE  6/6 PACG 1 0.7 2 22 9/30/2013 3 0 20 17 16 16 16 1 2 2 2 2 2 0.7 0.8  6/9  6/9  6/9  6/12  6/12 2 NIL
24 Hathija Kani 72 F
27 Selvam 47 M
28 Krishnan R 45 M
25 Ramanathan k r 58 M
26 Mahalakshmi 65 F
31 Gopalakrishnan 67 M
32 Ashraf k.p 46 M
29 Lakshmi S 50 F
30 Backialakshmi 45 F
35 Jamuna Rani 45 F
36 Alexander Michael 47 M
33 Rajasekar A 60 M
34 Selvarathinam 65 F
39 Rasak k 38 M
40 Subbulakshmi.K 43 F
37 Nambunayagi dharmaraj 50 F
38 Thapasu leela 48 F
 
 
KEY TO MASTER CHART 
RE  -  Right Eye 
LE  - Left Eye 
PACG - Primary Angle Closure Glaucoma 
CDR  - Cup to Disc Ratio 
IOP  - Intra Ocular Pressure 
LPI  - Laser Peripheral Iridectomy. 
Preop Gonioscopy 
1=>270-PAS 
2=>270+PAS 
0= <270 
Post op gonioscopy(3 months) 
1-Narrow without PAS 
2-Narrow-PAS 
3-Open/Narrow with patent ostium 
 
 
 
Visual fields- Presentation and 6 months 
1= Inferior Arcuate defect 
2=  Superior Arcuate defect 
3= Double Arcuate defect 
4=End stage, complete field loss 
0= Nasal step/ Temporal wedge 
LPI –total energy used 
1= <50mJ 
2= 50-60mJ 
3= >60mJ 
LPI Complications 
0=Nil 
1=Micro hyphaema 
2= Mild Uveitis/Iritis 
3=Corneal burns 
4= Repeat PI 
 
 
 
 
  
 
 
 
